id	sid	tid	token	lemma	pos
dpc-517	1	1	dermatology	dermatology	NOUN
dpc-517	1	2	:	:	PUNCT
dpc-517	1	3	practical	practical	ADJ
dpc-517	1	4	and	and	CCONJ
dpc-517	1	5	conceptual	conceptual	ADJ
dpc-517	1	6	4	4	NUM
dpc-517	1	7	research	research	NOUN
dpc-517	1	8	|	|	ADV
dpc-517	1	9	dermatol	dermatol	ADJ
dpc-517	1	10	pract	pract	NOUN
dpc-517	1	11	concept	concept	NOUN
dpc-517	1	12	2019;9(1):2	2019;9(1):2	PROPN
dpc-517	1	13	dermatology	dermatology	NOUN
dpc-517	1	14	practical	practical	ADJ
dpc-517	1	15	&	&	CCONJ
dpc-517	1	16	conceptual	conceptual	ADJ
dpc-517	1	17	comparing	compare	VERB
dpc-517	1	18	the	the	DET
dpc-517	1	19	efficacy	efficacy	NOUN
dpc-517	1	20	of	of	ADP
dpc-517	1	21	intralesional	intralesional	ADJ
dpc-517	1	22	triamcinolone	triamcinolone	NOUN
dpc-517	1	23	acetonide	acetonide	NOUN
dpc-517	1	24	with	with	ADP
dpc-517	1	25	verapamil	verapamil	NOUN
dpc-517	1	26	in	in	ADP
dpc-517	1	27	treatment	treatment	NOUN
dpc-517	1	28	of	of	ADP
dpc-517	1	29	keloids	keloid	NOUN
dpc-517	1	30	:	:	PUNCT
dpc-517	1	31	a	a	DET
dpc-517	1	32	randomized	randomized	ADJ
dpc-517	1	33	controlled	control	VERB
dpc-517	1	34	trial	trial	NOUN
dpc-517	1	35	nasrin	nasrin	NOUN
dpc-517	1	36	saki1	saki1	PROPN
dpc-517	1	37	,	,	PUNCT
dpc-517	1	38	raya	raya	PROPN
dpc-517	1	39	mokhtari2	mokhtari2	PROPN
dpc-517	1	40	,	,	PUNCT
dpc-517	1	41	farnoosh	farnoosh	ADJ
dpc-517	1	42	nozari3	nozari3	NOUN
dpc-517	1	43	1	1	NUM
dpc-517	1	44	molecular	molecular	ADJ
dpc-517	1	45	dermatology	dermatology	NOUN
dpc-517	1	46	research	research	NOUN
dpc-517	1	47	center	center	NOUN
dpc-517	1	48	,	,	PUNCT
dpc-517	1	49	shiraz	shiraz	PROPN
dpc-517	1	50	university	university	PROPN
dpc-517	1	51	of	of	ADP
dpc-517	1	52	medical	medical	ADJ
dpc-517	1	53	sciences	sciences	PROPN
dpc-517	1	54	,	,	PUNCT
dpc-517	1	55	shiraz	shiraz	PROPN
dpc-517	1	56	,	,	PUNCT
dpc-517	1	57	iran	iran	PROPN
dpc-517	1	58	2	2	NUM
dpc-517	1	59	dermatology	dermatology	NOUN
dpc-517	1	60	department	department	NOUN
dpc-517	1	61	,	,	PUNCT
dpc-517	1	62	shiraz	shiraz	PROPN
dpc-517	1	63	university	university	PROPN
dpc-517	1	64	of	of	ADP
dpc-517	1	65	medical	medical	ADJ
dpc-517	1	66	sciences	sciences	PROPN
dpc-517	1	67	,	,	PUNCT
dpc-517	1	68	shiraz	shiraz	PROPN
dpc-517	1	69	,	,	PUNCT
dpc-517	1	70	iran	iran	PROPN
dpc-517	1	71	3	3	NUM
dpc-517	1	72	student	student	NOUN
dpc-517	1	73	research	research	NOUN
dpc-517	1	74	committee	committee	NOUN
dpc-517	1	75	,	,	PUNCT
dpc-517	1	76	shiraz	shiraz	PROPN
dpc-517	1	77	university	university	PROPN
dpc-517	1	78	of	of	ADP
dpc-517	1	79	medical	medical	ADJ
dpc-517	1	80	sciences	sciences	PROPN
dpc-517	1	81	,	,	PUNCT
dpc-517	1	82	shiraz	shiraz	PROPN
dpc-517	1	83	,	,	PUNCT
dpc-517	1	84	iran	iran	PROPN
dpc-517	1	85	key	key	ADJ
dpc-517	1	86	words	word	NOUN
dpc-517	1	87	:	:	PUNCT
dpc-517	1	88	keloid	keloid	ADJ
dpc-517	1	89	,	,	PUNCT
dpc-517	1	90	verapamil	verapamil	NOUN
dpc-517	1	91	,	,	PUNCT
dpc-517	1	92	triamcinolone	triamcinolone	PROPN
dpc-517	1	93	,	,	PUNCT
dpc-517	1	94	vancouver	vancouver	PROPN
dpc-517	1	95	scar	scar	PROPN
dpc-517	1	96	scale	scale	PROPN
dpc-517	1	97	,	,	PUNCT
dpc-517	1	98	scar	scar	NOUN
dpc-517	1	99	citation	citation	NOUN
dpc-517	1	100	:	:	PUNCT
dpc-517	1	101	saki	saki	PROPN
dpc-517	1	102	n	n	CCONJ
dpc-517	1	103	,	,	PUNCT
dpc-517	1	104	mokhtari	mokhtari	PROPN
dpc-517	1	105	r	r	PROPN
dpc-517	1	106	,	,	PUNCT
dpc-517	1	107	nozari	nozari	PROPN
dpc-517	1	108	f.	f.	PROPN
dpc-517	1	109	comparing	compare	VERB
dpc-517	1	110	the	the	DET
dpc-517	1	111	efficacy	efficacy	NOUN
dpc-517	1	112	of	of	ADP
dpc-517	1	113	intralesional	intralesional	ADJ
dpc-517	1	114	triamcinolone	triamcinolone	NOUN
dpc-517	1	115	acetonide	acetonide	NOUN
dpc-517	1	116	with	with	ADP
dpc-517	1	117	verapamil	verapamil	NOUN
dpc-517	1	118	in	in	ADP
dpc-517	1	119	treatment	treatment	NOUN
dpc-517	1	120	of	of	ADP
dpc-517	1	121	keloids	keloid	NOUN
dpc-517	1	122	:	:	PUNCT
dpc-517	1	123	a	a	DET
dpc-517	1	124	randomized	randomized	ADJ
dpc-517	1	125	controlled	control	VERB
dpc-517	1	126	trial	trial	NOUN
dpc-517	1	127	.	.	PUNCT
dpc-517	2	1	dermatol	dermatol	NOUN
dpc-517	2	2	pract	pract	PROPN
dpc-517	2	3	concept	concept	NOUN
dpc-517	2	4	.	.	PUNCT
dpc-517	3	1	2019;9(1):4	2019;9(1):4	PROPN
dpc-517	3	2	-	-	PUNCT
dpc-517	3	3	9	9	NUM
dpc-517	3	4	.	.	PUNCT
dpc-517	3	5	doi	doi	NOUN
dpc-517	3	6	:	:	PUNCT
dpc-517	4	1	https://doi.org/10.5826/dpc.0901a02	https://doi.org/10.5826/dpc.0901a02	NOUN
dpc-517	4	2	published	publish	VERB
dpc-517	4	3	:	:	PUNCT
dpc-517	4	4	january	january	PROPN
dpc-517	4	5	31	31	NUM
dpc-517	4	6	,	,	PUNCT
dpc-517	4	7	2019	2019	NUM
dpc-517	4	8	copyright	copyright	NOUN
dpc-517	4	9	:	:	PUNCT
dpc-517	4	10	©	©	PROPN
dpc-517	4	11	2019	2019	NUM
dpc-517	4	12	saki	saki	PROPN
dpc-517	4	13	et	et	PROPN
dpc-517	4	14	 	 	SPACE
dpc-517	4	15	al	al	PROPN
dpc-517	4	16	.	.	PUNCT
dpc-517	5	1	this	this	PRON
dpc-517	5	2	is	be	AUX
dpc-517	5	3	an	an	DET
dpc-517	5	4	open	open	ADJ
dpc-517	5	5	-	-	PUNCT
dpc-517	5	6	access	access	NOUN
dpc-517	5	7	article	article	NOUN
dpc-517	5	8	distributed	distribute	VERB
dpc-517	5	9	under	under	ADP
dpc-517	5	10	the	the	DET
dpc-517	5	11	terms	term	NOUN
dpc-517	5	12	of	of	ADP
dpc-517	5	13	the	the	DET
dpc-517	5	14	creative	creative	ADJ
dpc-517	5	15	commons	common	NOUN
dpc-517	5	16	attribution	attribution	NOUN
dpc-517	5	17	license	license	NOUN
dpc-517	5	18	,	,	PUNCT
dpc-517	5	19	which	which	PRON
dpc-517	5	20	permits	permit	VERB
dpc-517	5	21	unrestricted	unrestricted	ADJ
dpc-517	5	22	use	use	NOUN
dpc-517	5	23	,	,	PUNCT
dpc-517	5	24	distribution	distribution	NOUN
dpc-517	5	25	,	,	PUNCT
dpc-517	5	26	and	and	CCONJ
dpc-517	5	27	reproduction	reproduction	NOUN
dpc-517	5	28	in	in	ADP
dpc-517	5	29	any	any	DET
dpc-517	5	30	medium	medium	NOUN
dpc-517	5	31	,	,	PUNCT
dpc-517	5	32	provided	provide	VERB
dpc-517	5	33	the	the	DET
dpc-517	5	34	original	original	ADJ
dpc-517	5	35	author	author	NOUN
dpc-517	5	36	and	and	CCONJ
dpc-517	5	37	source	source	NOUN
dpc-517	5	38	are	be	AUX
dpc-517	5	39	credited	credit	VERB
dpc-517	5	40	.	.	PUNCT
dpc-517	6	1	funding	funding	NOUN
dpc-517	6	2	:	:	PUNCT
dpc-517	6	3	none	none	NOUN
dpc-517	6	4	.	.	PUNCT
dpc-517	7	1	competing	compete	VERB
dpc-517	7	2	interests	interest	NOUN
dpc-517	7	3	:	:	PUNCT
dpc-517	7	4	the	the	DET
dpc-517	7	5	authors	author	NOUN
dpc-517	7	6	have	have	VERB
dpc-517	7	7	no	no	DET
dpc-517	7	8	conflicts	conflict	NOUN
dpc-517	7	9	of	of	ADP
dpc-517	7	10	interest	interest	NOUN
dpc-517	7	11	to	to	PART
dpc-517	7	12	disclose	disclose	VERB
dpc-517	7	13	.	.	PUNCT
dpc-517	8	1	authorship	authorship	NOUN
dpc-517	8	2	:	:	PUNCT
dpc-517	8	3	all	all	DET
dpc-517	8	4	authors	author	NOUN
dpc-517	8	5	have	have	AUX
dpc-517	8	6	contributed	contribute	VERB
dpc-517	8	7	significantly	significantly	ADV
dpc-517	8	8	to	to	ADP
dpc-517	8	9	this	this	DET
dpc-517	8	10	publication	publication	NOUN
dpc-517	8	11	.	.	PUNCT
dpc-517	9	1	corresponding	correspond	VERB
dpc-517	9	2	author	author	NOUN
dpc-517	9	3	:	:	PUNCT
dpc-517	9	4	farnoosh	farnoosh	PROPN
dpc-517	9	5	nozari	nozari	PROPN
dpc-517	9	6	,	,	PUNCT
dpc-517	9	7	student	student	NOUN
dpc-517	9	8	research	research	NOUN
dpc-517	9	9	committee	committee	PROPN
dpc-517	9	10	,	,	PUNCT
dpc-517	9	11	shiraz	shiraz	PROPN
dpc-517	9	12	university	university	PROPN
dpc-517	9	13	of	of	ADP
dpc-517	9	14	medical	medical	ADJ
dpc-517	9	15	sciences	sciences	PROPN
dpc-517	9	16	,	,	PUNCT
dpc-517	9	17	shiraz	shiraz	PROPN
dpc-517	9	18	,	,	PUNCT
dpc-517	9	19	iran	iran	PROPN
dpc-517	9	20	.	.	PUNCT
dpc-517	10	1	email	email	NOUN
dpc-517	10	2	:	:	PUNCT
dpc-517	10	3	farnoosh.nozari.7391@gmail.com	farnoosh.nozari.7391@gmail.com	X
dpc-517	10	4	background	background	NOUN
dpc-517	10	5	:	:	PUNCT
dpc-517	10	6	keloid	keloid	PROPN
dpc-517	10	7	management	management	NOUN
dpc-517	10	8	remains	remain	VERB
dpc-517	10	9	a	a	DET
dpc-517	10	10	challenging	challenging	ADJ
dpc-517	10	11	clinical	clinical	ADJ
dpc-517	10	12	problem	problem	NOUN
dpc-517	10	13	despite	despite	SCONJ
dpc-517	10	14	numerous	numerous	ADJ
dpc-517	10	15	therapies	therapy	NOUN
dpc-517	10	16	reported	report	VERB
dpc-517	10	17	until	until	ADP
dpc-517	10	18	now	now	ADV
dpc-517	10	19	.	.	PUNCT
dpc-517	11	1	the	the	DET
dpc-517	11	2	efficacy	efficacy	NOUN
dpc-517	11	3	of	of	ADP
dpc-517	11	4	corticosteroids	corticosteroid	NOUN
dpc-517	11	5	in	in	ADP
dpc-517	11	6	the	the	DET
dpc-517	11	7	treatment	treatment	NOUN
dpc-517	11	8	of	of	ADP
dpc-517	11	9	keloids	keloid	NOUN
dpc-517	11	10	has	have	AUX
dpc-517	11	11	been	be	AUX
dpc-517	11	12	well	well	ADV
dpc-517	11	13	established	establish	VERB
dpc-517	11	14	.	.	PUNCT
dpc-517	12	1	the	the	DET
dpc-517	12	2	most	most	ADV
dpc-517	12	3	commonly	commonly	ADV
dpc-517	12	4	used	use	VERB
dpc-517	12	5	corticosteroid	corticosteroid	NOUN
dpc-517	12	6	is	be	AUX
dpc-517	12	7	intralesional	intralesional	ADJ
dpc-517	12	8	triamcinolone	triamcinolone	NOUN
dpc-517	12	9	.	.	PUNCT
dpc-517	13	1	sporadic	sporadic	ADJ
dpc-517	13	2	reports	report	NOUN
dpc-517	13	3	on	on	ADP
dpc-517	13	4	the	the	DET
dpc-517	13	5	use	use	NOUN
dpc-517	13	6	of	of	ADP
dpc-517	13	7	intralesional	intralesional	ADJ
dpc-517	13	8	verapamil	verapamil	NOUN
dpc-517	13	9	suggest	suggest	VERB
dpc-517	13	10	its	its	PRON
dpc-517	13	11	efficacy	efficacy	NOUN
dpc-517	13	12	.	.	PUNCT
dpc-517	14	1	aim	aim	VERB
dpc-517	14	2	:	:	PUNCT
dpc-517	14	3	since	since	SCONJ
dpc-517	14	4	there	there	PRON
dpc-517	14	5	is	be	VERB
dpc-517	14	6	not	not	PART
dpc-517	14	7	sufficient	sufficient	ADJ
dpc-517	14	8	evidence	evidence	NOUN
dpc-517	14	9	to	to	PART
dpc-517	14	10	support	support	VERB
dpc-517	14	11	the	the	DET
dpc-517	14	12	role	role	NOUN
dpc-517	14	13	of	of	ADP
dpc-517	14	14	intralesional	intralesional	ADJ
dpc-517	14	15	verapamil	verapamil	NOUN
dpc-517	14	16	as	as	ADP
dpc-517	14	17	an	an	DET
dpc-517	14	18	effective	effective	ADJ
dpc-517	14	19	alternative	alternative	ADJ
dpc-517	14	20	modality	modality	NOUN
dpc-517	14	21	,	,	PUNCT
dpc-517	14	22	it	it	PRON
dpc-517	14	23	was	be	AUX
dpc-517	14	24	decided	decide	VERB
dpc-517	14	25	to	to	PART
dpc-517	14	26	undertake	undertake	VERB
dpc-517	14	27	a	a	DET
dpc-517	14	28	randomized	randomized	ADJ
dpc-517	14	29	study	study	NOUN
dpc-517	14	30	to	to	PART
dpc-517	14	31	determine	determine	VERB
dpc-517	14	32	its	its	PRON
dpc-517	14	33	efficacy	efficacy	NOUN
dpc-517	14	34	as	as	ADP
dpc-517	14	35	a	a	DET
dpc-517	14	36	treatment	treatment	NOUN
dpc-517	14	37	for	for	ADP
dpc-517	14	38	keloids	keloid	NOUN
dpc-517	14	39	.	.	PUNCT
dpc-517	15	1	methods	method	NOUN
dpc-517	15	2	:	:	PUNCT
dpc-517	15	3	a	a	DET
dpc-517	15	4	randomized	randomized	ADJ
dpc-517	15	5	,	,	PUNCT
dpc-517	15	6	single	single	ADJ
dpc-517	15	7	-	-	PUNCT
dpc-517	15	8	blind	blind	ADJ
dpc-517	15	9	,	,	PUNCT
dpc-517	15	10	single	single	ADJ
dpc-517	15	11	-	-	PUNCT
dpc-517	15	12	group	group	NOUN
dpc-517	15	13	comparison	comparison	NOUN
dpc-517	15	14	with	with	ADP
dpc-517	15	15	15	15	NUM
dpc-517	15	16	patients	patient	NOUN
dpc-517	15	17	(	(	PUNCT
dpc-517	15	18	30	30	NUM
dpc-517	15	19	scars	scar	NOUN
dpc-517	15	20	)	)	PUNCT
dpc-517	15	21	was	be	AUX
dpc-517	15	22	carried	carry	VERB
dpc-517	15	23	out	out	ADP
dpc-517	15	24	to	to	PART
dpc-517	15	25	compare	compare	VERB
dpc-517	15	26	the	the	DET
dpc-517	15	27	effects	effect	NOUN
dpc-517	15	28	of	of	ADP
dpc-517	15	29	intralesional	intralesional	ADJ
dpc-517	15	30	triamcinolone	triamcinolone	NOUN
dpc-517	15	31	with	with	ADP
dpc-517	15	32	verapamil	verapamil	NOUN
dpc-517	15	33	injections	injection	NOUN
dpc-517	15	34	.	.	PUNCT
dpc-517	16	1	injections	injection	NOUN
dpc-517	16	2	were	be	AUX
dpc-517	16	3	scheduled	schedule	VERB
dpc-517	16	4	every	every	DET
dpc-517	16	5	3	3	NUM
dpc-517	16	6	weeks	week	NOUN
dpc-517	16	7	accompanied	accompany	VERB
dpc-517	16	8	by	by	ADP
dpc-517	16	9	cryotherapy	cryotherapy	NOUN
dpc-517	16	10	until	until	ADP
dpc-517	16	11	complete	complete	ADJ
dpc-517	16	12	flattening	flattening	NOUN
dpc-517	16	13	of	of	ADP
dpc-517	16	14	the	the	DET
dpc-517	16	15	scar	scar	NOUN
dpc-517	16	16	or	or	CCONJ
dpc-517	16	17	maximum	maximum	ADJ
dpc-517	16	18	8	8	NUM
dpc-517	16	19	sessions	session	NOUN
dpc-517	16	20	,	,	PUNCT
dpc-517	16	21	whichever	whichever	PRON
dpc-517	16	22	came	come	VERB
dpc-517	16	23	earlier	early	ADV
dpc-517	16	24	.	.	PUNCT
dpc-517	17	1	scar	scar	ADJ
dpc-517	17	2	evaluation	evaluation	NOUN
dpc-517	17	3	at	at	ADP
dpc-517	17	4	each	each	DET
dpc-517	17	5	stage	stage	NOUN
dpc-517	17	6	was	be	AUX
dpc-517	17	7	done	do	VERB
dpc-517	17	8	by	by	ADP
dpc-517	17	9	serial	serial	ADJ
dpc-517	17	10	photographic	photographic	ADJ
dpc-517	17	11	records	record	NOUN
dpc-517	17	12	as	as	ADV
dpc-517	17	13	well	well	ADV
dpc-517	17	14	as	as	ADP
dpc-517	17	15	by	by	ADP
dpc-517	17	16	vancouver	vancouver	PROPN
dpc-517	17	17	scar	scar	PROPN
dpc-517	17	18	scale	scale	NOUN
dpc-517	17	19	.	.	PUNCT
dpc-517	18	1	statistical	statistical	ADJ
dpc-517	18	2	analysis	analysis	NOUN
dpc-517	18	3	was	be	AUX
dpc-517	18	4	done	do	VERB
dpc-517	18	5	by	by	ADP
dpc-517	18	6	wilcoxon	wilcoxon	ADJ
dpc-517	18	7	and	and	CCONJ
dpc-517	18	8	mann	mann	PROPN
dpc-517	18	9	-	-	PUNCT
dpc-517	18	10	whitney	whitney	PROPN
dpc-517	18	11	u	u	NOUN
dpc-517	18	12	tests	test	VERB
dpc-517	18	13	using	use	VERB
dpc-517	18	14	spss	spss	PROPN
dpc-517	18	15	version	version	PROPN
dpc-517	18	16	19	19	NUM
dpc-517	18	17	.	.	PUNCT
dpc-517	19	1	results	result	NOUN
dpc-517	19	2	:	:	PUNCT
dpc-517	19	3	in	in	ADP
dpc-517	19	4	both	both	DET
dpc-517	19	5	study	study	NOUN
dpc-517	19	6	groups	group	NOUN
dpc-517	19	7	there	there	PRON
dpc-517	19	8	was	be	VERB
dpc-517	19	9	a	a	DET
dpc-517	19	10	reduction	reduction	NOUN
dpc-517	19	11	in	in	ADP
dpc-517	19	12	height	height	NOUN
dpc-517	19	13	and	and	CCONJ
dpc-517	19	14	pliability	pliability	NOUN
dpc-517	19	15	at	at	ADP
dpc-517	19	16	the	the	DET
dpc-517	19	17	end	end	NOUN
dpc-517	19	18	of	of	ADP
dpc-517	19	19	the	the	DET
dpc-517	19	20	study	study	NOUN
dpc-517	19	21	.	.	PUNCT
dpc-517	20	1	better	well	ADJ
dpc-517	20	2	improvement	improvement	NOUN
dpc-517	20	3	in	in	ADP
dpc-517	20	4	height	height	NOUN
dpc-517	20	5	and	and	CCONJ
dpc-517	20	6	pliability	pliability	NOUN
dpc-517	20	7	was	be	AUX
dpc-517	20	8	seen	see	VERB
dpc-517	20	9	with	with	ADP
dpc-517	20	10	triamcinolone	triamcinolone	NOUN
dpc-517	20	11	in	in	ADP
dpc-517	20	12	comparison	comparison	NOUN
dpc-517	20	13	with	with	ADP
dpc-517	20	14	verapamil	verapamil	NOUN
dpc-517	20	15	.	.	PUNCT
dpc-517	21	1	however	however	ADV
dpc-517	21	2	,	,	PUNCT
dpc-517	21	3	a	a	DET
dpc-517	21	4	desired	desire	VERB
dpc-517	21	5	change	change	NOUN
dpc-517	21	6	in	in	ADP
dpc-517	21	7	vascularity	vascularity	NOUN
dpc-517	21	8	and	and	CCONJ
dpc-517	21	9	pigmentation	pigmentation	NOUN
dpc-517	21	10	was	be	AUX
dpc-517	21	11	not	not	PART
dpc-517	21	12	seen	see	VERB
dpc-517	21	13	with	with	ADP
dpc-517	21	14	either	either	PRON
dpc-517	21	15	of	of	ADP
dpc-517	21	16	the	the	DET
dpc-517	21	17	drugs	drug	NOUN
dpc-517	21	18	.	.	PUNCT
dpc-517	22	1	conclusion	conclusion	NOUN
dpc-517	22	2	:	:	PUNCT
dpc-517	22	3	verapamil	verapamil	NOUN
dpc-517	22	4	is	be	AUX
dpc-517	22	5	not	not	PART
dpc-517	22	6	as	as	ADV
dpc-517	22	7	effective	effective	ADJ
dpc-517	22	8	as	as	ADP
dpc-517	22	9	triamcinolone	triamcinolone	NOUN
dpc-517	22	10	in	in	ADP
dpc-517	22	11	the	the	DET
dpc-517	22	12	treatment	treatment	NOUN
dpc-517	22	13	of	of	ADP
dpc-517	22	14	keloids	keloid	NOUN
dpc-517	22	15	.	.	PUNCT
dpc-517	23	1	abstract	abstract	ADJ
dpc-517	23	2	research	research	NOUN
dpc-517	23	3	|	|	ADV
dpc-517	23	4	dermatol	dermatol	ADJ
dpc-517	23	5	pract	pract	NOUN
dpc-517	23	6	concept	concept	NOUN
dpc-517	23	7	2019;9(1):2	2019;9(1):2	PROPN
dpc-517	23	8	5	5	NUM
dpc-517	23	9	of	of	ADP
dpc-517	23	10	prior	prior	ADJ
dpc-517	23	11	treatment	treatment	NOUN
dpc-517	23	12	with	with	ADP
dpc-517	23	13	any	any	DET
dpc-517	23	14	intralesional	intralesional	ADJ
dpc-517	23	15	injections	injection	NOUN
dpc-517	23	16	were	be	AUX
dpc-517	23	17	excluded	exclude	VERB
dpc-517	23	18	from	from	ADP
dpc-517	23	19	the	the	DET
dpc-517	23	20	study	study	NOUN
dpc-517	23	21	.	.	PUNCT
dpc-517	24	1	the	the	DET
dpc-517	24	2	minimum	minimum	ADJ
dpc-517	24	3	sample	sample	NOUN
dpc-517	24	4	size	size	NOUN
dpc-517	24	5	of	of	ADP
dpc-517	24	6	15	15	NUM
dpc-517	24	7	patients	patient	NOUN
dpc-517	24	8	with	with	ADP
dpc-517	24	9	at	at	ADV
dpc-517	24	10	least	least	ADJ
dpc-517	24	11	2	2	NUM
dpc-517	24	12	scars	scar	NOUN
dpc-517	24	13	(	(	PUNCT
dpc-517	24	14	30	30	NUM
dpc-517	24	15	scars	scar	NOUN
dpc-517	24	16	)	)	PUNCT
dpc-517	24	17	was	be	AUX
dpc-517	24	18	calculated	calculate	VERB
dpc-517	24	19	for	for	ADP
dpc-517	24	20	this	this	DET
dpc-517	24	21	trial	trial	NOUN
dpc-517	24	22	,	,	PUNCT
dpc-517	24	23	where	where	SCONJ
dpc-517	24	24	triamcinolone	triamcinolone	NOUN
dpc-517	24	25	was	be	AUX
dpc-517	24	26	considered	consider	VERB
dpc-517	24	27	as	as	SCONJ
dpc-517	24	28	the	the	DET
dpc-517	24	29	standard	standard	ADJ
dpc-517	24	30	treatment	treatment	NOUN
dpc-517	24	31	and	and	CCONJ
dpc-517	24	32	verapamil	verapamil	NOUN
dpc-517	24	33	was	be	AUX
dpc-517	24	34	regarded	regard	VERB
dpc-517	24	35	as	as	ADP
dpc-517	24	36	the	the	DET
dpc-517	24	37	experimental	experimental	ADJ
dpc-517	24	38	drug	drug	NOUN
dpc-517	24	39	.	.	PUNCT
dpc-517	25	1	fifteen	fifteen	NUM
dpc-517	25	2	consecutive	consecutive	ADJ
dpc-517	25	3	patients	patient	NOUN
dpc-517	25	4	who	who	PRON
dpc-517	25	5	fulfilled	fulfil	VERB
dpc-517	25	6	our	our	PRON
dpc-517	25	7	inclusion	inclusion	NOUN
dpc-517	25	8	criteria	criterion	NOUN
dpc-517	25	9	entered	enter	VERB
dpc-517	25	10	the	the	DET
dpc-517	25	11	study	study	NOUN
dpc-517	25	12	using	use	VERB
dpc-517	25	13	simple	simple	ADJ
dpc-517	25	14	randomization	randomization	NOUN
dpc-517	25	15	technique	technique	NOUN
dpc-517	25	16	.	.	PUNCT
dpc-517	26	1	two	two	NUM
dpc-517	26	2	similar	similar	ADJ
dpc-517	26	3	keloid	keloid	NOUN
dpc-517	26	4	scars	scar	NOUN
dpc-517	26	5	of	of	ADP
dpc-517	26	6	each	each	DET
dpc-517	26	7	patient	patient	NOUN
dpc-517	26	8	were	be	AUX
dpc-517	26	9	randomly	randomly	ADV
dpc-517	26	10	selected	select	VERB
dpc-517	26	11	,	,	PUNCT
dpc-517	26	12	using	use	VERB
dpc-517	26	13	simple	simple	ADJ
dpc-517	26	14	randomization	randomization	NOUN
dpc-517	26	15	by	by	ADP
dpc-517	26	16	random	random	ADJ
dpc-517	26	17	number	number	NOUN
dpc-517	26	18	table	table	NOUN
dpc-517	26	19	.	.	PUNCT
dpc-517	27	1	deciding	decide	VERB
dpc-517	27	2	on	on	ADP
dpc-517	27	3	putting	put	VERB
dpc-517	27	4	which	which	DET
dpc-517	27	5	lesion	lesion	NOUN
dpc-517	27	6	into	into	ADP
dpc-517	27	7	which	which	PRON
dpc-517	27	8	therapeutic	therapeutic	ADJ
dpc-517	27	9	arm	arm	NOUN
dpc-517	27	10	was	be	AUX
dpc-517	27	11	randomly	randomly	ADV
dpc-517	27	12	made	make	VERB
dpc-517	27	13	by	by	ADP
dpc-517	27	14	flipping	flip	VERB
dpc-517	27	15	a	a	DET
dpc-517	27	16	coin	coin	NOUN
dpc-517	27	17	.	.	PUNCT
dpc-517	28	1	a	a	DET
dpc-517	28	2	lidocaine	lidocaine	NOUN
dpc-517	28	3	2	2	NUM
dpc-517	28	4	injection	injection	NOUN
dpc-517	28	5	with	with	ADP
dpc-517	28	6	ring	ring	NOUN
dpc-517	28	7	block	block	NOUN
dpc-517	28	8	technique	technique	NOUN
dpc-517	28	9	was	be	AUX
dpc-517	28	10	used	use	VERB
dpc-517	28	11	to	to	PART
dpc-517	28	12	anaesthetize	anaesthetize	VERB
dpc-517	28	13	the	the	DET
dpc-517	28	14	site	site	NOUN
dpc-517	28	15	of	of	ADP
dpc-517	28	16	injection	injection	NOUN
dpc-517	28	17	before	before	ADP
dpc-517	28	18	starting	start	VERB
dpc-517	28	19	the	the	DET
dpc-517	28	20	treatment	treatment	NOUN
dpc-517	28	21	.	.	PUNCT
dpc-517	29	1	the	the	DET
dpc-517	29	2	injections	injection	NOUN
dpc-517	29	3	were	be	AUX
dpc-517	29	4	made	make	VERB
dpc-517	29	5	with	with	ADP
dpc-517	29	6	an	an	DET
dpc-517	29	7	insulin	insulin	NOUN
dpc-517	29	8	syringe	syringe	NOUN
dpc-517	29	9	,	,	PUNCT
dpc-517	29	10	27	27	NUM
dpc-517	29	11	-	-	PUNCT
dpc-517	29	12	gauge	gauge	NOUN
dpc-517	29	13	needle	needle	NOUN
dpc-517	29	14	.	.	PUNCT
dpc-517	30	1	one	one	NUM
dpc-517	30	2	of	of	ADP
dpc-517	30	3	the	the	DET
dpc-517	30	4	scars	scar	NOUN
dpc-517	30	5	received	receive	VERB
dpc-517	30	6	intralesional	intralesional	ADJ
dpc-517	30	7	tac	tac	PROPN
dpc-517	30	8	(	(	PUNCT
dpc-517	30	9	exir	exir	PROPN
dpc-517	30	10	pharmaceutical	pharmaceutical	PROPN
dpc-517	30	11	co	co	NOUN
dpc-517	30	12	,	,	PUNCT
dpc-517	30	13	borujerd	borujerd	NOUN
dpc-517	30	14	,	,	PUNCT
dpc-517	30	15	iran	iran	PROPN
dpc-517	30	16	)	)	PUNCT
dpc-517	30	17	,	,	PUNCT
dpc-517	30	18	while	while	SCONJ
dpc-517	30	19	the	the	DET
dpc-517	30	20	other	other	ADJ
dpc-517	30	21	received	receive	VERB
dpc-517	30	22	intralesional	intralesional	ADJ
dpc-517	30	23	verapamil	verapamil	NOUN
dpc-517	30	24	hydrochloride	hydrochloride	NOUN
dpc-517	30	25	(	(	PUNCT
dpc-517	30	26	verahexal	verahexal	NOUN
dpc-517	30	27	,	,	PUNCT
dpc-517	30	28	knoll	knoll	PROPN
dpc-517	30	29	ag	ag	PROPN
dpc-517	30	30	,	,	PUNCT
dpc-517	30	31	ludwigshafen	ludwigshafen	NOUN
dpc-517	30	32	,	,	PUNCT
dpc-517	30	33	germany	germany	PROPN
dpc-517	30	34	)	)	PUNCT
dpc-517	30	35	every	every	DET
dpc-517	30	36	3	3	NUM
dpc-517	30	37	weeks	week	NOUN
dpc-517	30	38	for	for	ADP
dpc-517	30	39	a	a	DET
dpc-517	30	40	maximum	maximum	NOUN
dpc-517	30	41	of	of	ADP
dpc-517	30	42	8	8	NUM
dpc-517	30	43	sessions	session	NOUN
dpc-517	30	44	or	or	CCONJ
dpc-517	30	45	until	until	ADP
dpc-517	30	46	complete	complete	ADJ
dpc-517	30	47	flattening	flattening	NOUN
dpc-517	30	48	of	of	ADP
dpc-517	30	49	the	the	DET
dpc-517	30	50	scar	scar	NOUN
dpc-517	30	51	.	.	PUNCT
dpc-517	31	1	each	each	DET
dpc-517	31	2	intralesional	intralesional	ADJ
dpc-517	31	3	session	session	NOUN
dpc-517	31	4	was	be	AUX
dpc-517	31	5	preceded	precede	VERB
dpc-517	31	6	by	by	ADP
dpc-517	31	7	cryotherapy	cryotherapy	NOUN
dpc-517	31	8	using	use	VERB
dpc-517	31	9	cryospray	cryospray	ADJ
dpc-517	31	10	technique	technique	NOUN
dpc-517	31	11	for	for	ADP
dpc-517	31	12	20	20	NUM
dpc-517	31	13	seconds	second	NOUN
dpc-517	31	14	at	at	ADP
dpc-517	31	15	1	1	NUM
dpc-517	31	16	cm	cm	NOUN
dpc-517	31	17	distance	distance	NOUN
dpc-517	31	18	from	from	ADP
dpc-517	31	19	the	the	DET
dpc-517	31	20	lesion	lesion	NOUN
dpc-517	31	21	.	.	PUNCT
dpc-517	32	1	the	the	DET
dpc-517	32	2	maximum	maximum	ADJ
dpc-517	32	3	volume	volume	NOUN
dpc-517	32	4	of	of	ADP
dpc-517	32	5	triamcinolone	triamcinolone	NOUN
dpc-517	32	6	(	(	PUNCT
dpc-517	32	7	20	20	NUM
dpc-517	32	8	mg/	mg/	NOUN
dpc-517	32	9	ml	ml	NOUN
dpc-517	32	10	)	)	PUNCT
dpc-517	32	11	and	and	CCONJ
dpc-517	32	12	verapamil	verapamil	NOUN
dpc-517	32	13	(	(	PUNCT
dpc-517	32	14	2.5	2.5	NUM
dpc-517	32	15	mg	mg	NUM
dpc-517	32	16	/	/	SYM
dpc-517	32	17	ml	ml	NOUN
dpc-517	32	18	)	)	PUNCT
dpc-517	32	19	at	at	ADP
dpc-517	32	20	each	each	DET
dpc-517	32	21	session	session	NOUN
dpc-517	32	22	was	be	AUX
dpc-517	32	23	1.5	1.5	NUM
dpc-517	32	24	cc	cc	NOUN
dpc-517	32	25	.	.	PUNCT
dpc-517	33	1	we	we	PRON
dpc-517	33	2	used	use	VERB
dpc-517	33	3	multiple	multiple	ADJ
dpc-517	33	4	intralesional	intralesional	ADJ
dpc-517	33	5	injections	injection	NOUN
dpc-517	33	6	until	until	SCONJ
dpc-517	33	7	the	the	DET
dpc-517	33	8	lesion	lesion	NOUN
dpc-517	33	9	was	be	AUX
dpc-517	33	10	blanched	blanch	VERB
dpc-517	33	11	.	.	PUNCT
dpc-517	34	1	detailed	detailed	ADJ
dpc-517	34	2	history	history	NOUN
dpc-517	34	3	and	and	CCONJ
dpc-517	34	4	demographic	demographic	ADJ
dpc-517	34	5	parameters	parameter	NOUN
dpc-517	34	6	including	include	VERB
dpc-517	34	7	age	age	NOUN
dpc-517	34	8	,	,	PUNCT
dpc-517	34	9	sex	sex	NOUN
dpc-517	34	10	,	,	PUNCT
dpc-517	34	11	duration	duration	NOUN
dpc-517	34	12	of	of	ADP
dpc-517	34	13	the	the	DET
dpc-517	34	14	scar	scar	NOUN
dpc-517	34	15	,	,	PUNCT
dpc-517	34	16	and	and	CCONJ
dpc-517	34	17	prior	prior	ADJ
dpc-517	34	18	treatments	treatment	NOUN
dpc-517	34	19	were	be	AUX
dpc-517	34	20	recorded	record	VERB
dpc-517	34	21	.	.	PUNCT
dpc-517	35	1	scar	scar	ADJ
dpc-517	35	2	evaluation	evaluation	NOUN
dpc-517	35	3	at	at	ADP
dpc-517	35	4	each	each	DET
dpc-517	35	5	stage	stage	NOUN
dpc-517	35	6	was	be	AUX
dpc-517	35	7	done	do	VERB
dpc-517	35	8	by	by	ADP
dpc-517	35	9	vancouver	vancouver	PROPN
dpc-517	35	10	scar	scar	PROPN
dpc-517	35	11	scale	scale	NOUN
dpc-517	35	12	(	(	PUNCT
dpc-517	35	13	vss	vss	NOUN
dpc-517	35	14	)	)	PUNCT
dpc-517	36	1	[	[	X
dpc-517	36	2	8	8	NUM
dpc-517	36	3	]	]	PUNCT
dpc-517	36	4	.	.	PUNCT
dpc-517	37	1	the	the	DET
dpc-517	37	2	mentioned	mention	VERB
dpc-517	37	3	scale	scale	NOUN
dpc-517	37	4	scores	score	VERB
dpc-517	37	5	the	the	DET
dpc-517	37	6	scars	scar	NOUN
dpc-517	37	7	on	on	ADP
dpc-517	37	8	4	4	NUM
dpc-517	37	9	parameters	parameter	NOUN
dpc-517	37	10	:	:	PUNCT
dpc-517	37	11	height	height	NOUN
dpc-517	37	12	,	,	PUNCT
dpc-517	37	13	vascularity	vascularity	NOUN
dpc-517	37	14	,	,	PUNCT
dpc-517	37	15	pliability	pliability	NOUN
dpc-517	37	16	,	,	PUNCT
dpc-517	37	17	and	and	CCONJ
dpc-517	37	18	pigmentation	pigmentation	NOUN
dpc-517	37	19	.	.	PUNCT
dpc-517	38	1	scar	scar	ADJ
dpc-517	38	2	height	height	NOUN
dpc-517	38	3	was	be	AUX
dpc-517	38	4	accurately	accurately	ADV
dpc-517	38	5	measured	measure	VERB
dpc-517	38	6	with	with	ADP
dpc-517	38	7	a	a	DET
dpc-517	38	8	ruler	ruler	NOUN
dpc-517	38	9	in	in	ADP
dpc-517	38	10	millimeters	millimeters	PROPN
dpc-517	38	11	.	.	PUNCT
dpc-517	39	1	scar	scar	ADJ
dpc-517	39	2	vascularity	vascularity	NOUN
dpc-517	39	3	and	and	CCONJ
dpc-517	39	4	pigmentation	pigmentation	NOUN
dpc-517	39	5	were	be	AUX
dpc-517	39	6	assessed	assess	VERB
dpc-517	39	7	by	by	ADP
dpc-517	39	8	visual	visual	ADJ
dpc-517	39	9	inspection	inspection	NOUN
dpc-517	39	10	.	.	PUNCT
dpc-517	40	1	scar	scar	ADJ
dpc-517	40	2	pliability	pliability	NOUN
dpc-517	40	3	was	be	AUX
dpc-517	40	4	subjectively	subjectively	ADV
dpc-517	40	5	assessed	assess	VERB
dpc-517	40	6	by	by	ADP
dpc-517	40	7	palpation	palpation	NOUN
dpc-517	40	8	.	.	PUNCT
dpc-517	41	1	for	for	ADP
dpc-517	41	2	study	study	NOUN
dpc-517	41	3	parameters	parameter	NOUN
dpc-517	41	4	in	in	ADP
dpc-517	41	5	each	each	DET
dpc-517	41	6	group	group	NOUN
dpc-517	41	7	,	,	PUNCT
dpc-517	41	8	the	the	DET
dpc-517	41	9	mean	mean	ADJ
dpc-517	41	10	value	value	NOUN
dpc-517	41	11	and	and	CCONJ
dpc-517	41	12	standard	standard	ADJ
dpc-517	41	13	deviation	deviation	NOUN
dpc-517	41	14	(	(	PUNCT
dpc-517	41	15	sd	sd	NOUN
dpc-517	41	16	)	)	PUNCT
dpc-517	41	17	were	be	AUX
dpc-517	41	18	calculated	calculate	VERB
dpc-517	41	19	.	.	PUNCT
dpc-517	42	1	the	the	DET
dpc-517	42	2	decreasing	decrease	VERB
dpc-517	42	3	values	value	NOUN
dpc-517	42	4	reflect	reflect	VERB
dpc-517	42	5	the	the	DET
dpc-517	42	6	clinical	clinical	ADJ
dpc-517	42	7	improvement	improvement	NOUN
dpc-517	42	8	of	of	ADP
dpc-517	42	9	the	the	DET
dpc-517	42	10	scar	scar	NOUN
dpc-517	42	11	.	.	PUNCT
dpc-517	42	12	 	 	SPACE
dpc-517	43	1	the	the	DET
dpc-517	43	2	wilcoxon	wilcoxon	ADJ
dpc-517	43	3	test	test	NOUN
dpc-517	43	4	was	be	AUX
dpc-517	43	5	used	use	VERB
dpc-517	43	6	to	to	PART
dpc-517	43	7	test	test	VERB
dpc-517	43	8	the	the	DET
dpc-517	43	9	significant	significant	ADJ
dpc-517	43	10	improvement	improvement	NOUN
dpc-517	43	11	of	of	ADP
dpc-517	43	12	vss	vss	NOUN
dpc-517	43	13	parameters	parameter	NOUN
dpc-517	43	14	in	in	ADP
dpc-517	43	15	each	each	DET
dpc-517	43	16	group	group	NOUN
dpc-517	43	17	.	.	PUNCT
dpc-517	44	1	the	the	DET
dpc-517	44	2	vss	vss	NOUN
dpc-517	44	3	scores	score	NOUN
dpc-517	44	4	were	be	AUX
dpc-517	44	5	compared	compare	VERB
dpc-517	44	6	between	between	ADP
dpc-517	44	7	the	the	DET
dpc-517	44	8	2	2	NUM
dpc-517	44	9	groups	group	NOUN
dpc-517	44	10	using	use	VERB
dpc-517	44	11	mann	mann	PROPN
dpc-517	44	12	-	-	PUNCT
dpc-517	44	13	whitney	whitney	PROPN
dpc-517	44	14	u	u	PROPN
dpc-517	44	15	test	test	NOUN
dpc-517	44	16	.	.	PUNCT
dpc-517	45	1	p	p	NOUN
dpc-517	45	2	value	value	NOUN
dpc-517	45	3	<	<	NOUN
dpc-517	45	4	0.05	0.05	NUM
dpc-517	45	5	was	be	AUX
dpc-517	45	6	considered	consider	VERB
dpc-517	45	7	to	to	PART
dpc-517	45	8	be	be	AUX
dpc-517	45	9	statistically	statistically	ADV
dpc-517	45	10	significant	significant	ADJ
dpc-517	45	11	.	.	PUNCT
dpc-517	46	1	statistical	statistical	ADJ
dpc-517	46	2	analysis	analysis	NOUN
dpc-517	46	3	was	be	AUX
dpc-517	46	4	done	do	VERB
dpc-517	46	5	using	use	VERB
dpc-517	46	6	spss	spss	PROPN
dpc-517	46	7	version	version	NOUN
dpc-517	46	8	19	19	NUM
dpc-517	46	9	.	.	PUNCT
dpc-517	47	1	results	result	VERB
dpc-517	47	2	thirty	thirty	NUM
dpc-517	47	3	scars	scar	NOUN
dpc-517	47	4	were	be	AUX
dpc-517	47	5	studied	study	VERB
dpc-517	47	6	in	in	ADP
dpc-517	47	7	15	15	NUM
dpc-517	47	8	randomly	randomly	ADV
dpc-517	47	9	selected	select	VERB
dpc-517	47	10	patients	patient	NOUN
dpc-517	47	11	who	who	PRON
dpc-517	47	12	met	meet	VERB
dpc-517	47	13	our	our	PRON
dpc-517	47	14	inclusion	inclusion	NOUN
dpc-517	47	15	criteria	criterion	NOUN
dpc-517	47	16	(	(	PUNCT
dpc-517	47	17	15	15	NUM
dpc-517	47	18	scars	scar	NOUN
dpc-517	47	19	treated	treat	VERB
dpc-517	47	20	with	with	ADP
dpc-517	47	21	verapamil	verapamil	NOUN
dpc-517	47	22	;	;	PUNCT
dpc-517	47	23	15	15	NUM
dpc-517	47	24	scars	scar	NOUN
dpc-517	47	25	treated	treat	VERB
dpc-517	47	26	with	with	ADP
dpc-517	47	27	triamcinolone	triamcinolone	NOUN
dpc-517	47	28	)	)	PUNCT
dpc-517	47	29	.	.	PUNCT
dpc-517	48	1	among	among	ADP
dpc-517	48	2	15	15	NUM
dpc-517	48	3	participants	participant	NOUN
dpc-517	48	4	,	,	PUNCT
dpc-517	48	5	14	14	NUM
dpc-517	48	6	were	be	AUX
dpc-517	48	7	female	female	ADJ
dpc-517	48	8	and	and	CCONJ
dpc-517	48	9	1	1	NUM
dpc-517	48	10	was	be	AUX
dpc-517	48	11	male	male	ADJ
dpc-517	48	12	.	.	PUNCT
dpc-517	49	1	the	the	DET
dpc-517	49	2	mean	mean	ADJ
dpc-517	49	3	age	age	NOUN
dpc-517	49	4	of	of	ADP
dpc-517	49	5	the	the	DET
dpc-517	49	6	patients	patient	NOUN
dpc-517	49	7	was	be	AUX
dpc-517	49	8	31.53	31.53	NUM
dpc-517	49	9	±	±	NUM
dpc-517	49	10	12.58	12.58	NUM
dpc-517	49	11	years	year	NOUN
dpc-517	49	12	(	(	PUNCT
dpc-517	49	13	mean	mean	PROPN
dpc-517	49	14	±	±	NUM
dpc-517	49	15	sd	sd	NOUN
dpc-517	49	16	)	)	PUNCT
dpc-517	49	17	and	and	CCONJ
dpc-517	49	18	the	the	DET
dpc-517	49	19	mean	mean	ADJ
dpc-517	49	20	duration	duration	NOUN
dpc-517	49	21	of	of	ADP
dpc-517	49	22	the	the	DET
dpc-517	49	23	disease	disease	NOUN
dpc-517	49	24	was	be	AUX
dpc-517	49	25	11.46	11.46	NUM
dpc-517	49	26	±	±	NUM
dpc-517	49	27	7.06	7.06	NUM
dpc-517	49	28	months	month	NOUN
dpc-517	49	29	.	.	PUNCT
dpc-517	50	1	introduction	introduction	NOUN
dpc-517	50	2	characterized	characterize	VERB
dpc-517	50	3	by	by	ADP
dpc-517	50	4	firm	firm	ADJ
dpc-517	50	5	,	,	PUNCT
dpc-517	50	6	tender	tender	ADJ
dpc-517	50	7	nodules	nodule	NOUN
dpc-517	50	8	or	or	CCONJ
dpc-517	50	9	plaques	plaque	NOUN
dpc-517	50	10	,	,	PUNCT
dpc-517	50	11	keloids	keloid	NOUN
dpc-517	50	12	occur	occur	VERB
dpc-517	50	13	more	more	ADV
dpc-517	50	14	frequently	frequently	ADV
dpc-517	50	15	on	on	ADP
dpc-517	50	16	shoulders	shoulder	NOUN
dpc-517	50	17	,	,	PUNCT
dpc-517	50	18	chest	chest	NOUN
dpc-517	50	19	,	,	PUNCT
dpc-517	50	20	neck	neck	NOUN
dpc-517	50	21	,	,	PUNCT
dpc-517	50	22	upper	upper	ADJ
dpc-517	50	23	arms	arm	NOUN
dpc-517	50	24	,	,	PUNCT
dpc-517	50	25	and	and	CCONJ
dpc-517	50	26	face	face	VERB
dpc-517	50	27	[	[	X
dpc-517	50	28	1	1	NUM
dpc-517	50	29	]	]	PUNCT
dpc-517	50	30	.	.	PUNCT
dpc-517	51	1	they	they	PRON
dpc-517	51	2	are	be	AUX
dpc-517	51	3	benign	benign	ADJ
dpc-517	51	4	overgrowth	overgrowth	NOUN
dpc-517	51	5	of	of	ADP
dpc-517	51	6	fibrous	fibrous	ADJ
dpc-517	51	7	tissue	tissue	NOUN
dpc-517	51	8	,	,	PUNCT
dpc-517	51	9	usually	usually	ADV
dpc-517	51	10	developing	develop	VERB
dpc-517	51	11	after	after	ADP
dpc-517	51	12	healing	healing	NOUN
dpc-517	51	13	of	of	ADP
dpc-517	51	14	a	a	DET
dpc-517	51	15	skin	skin	NOUN
dpc-517	51	16	injury	injury	NOUN
dpc-517	51	17	due	due	ADP
dpc-517	51	18	to	to	ADP
dpc-517	51	19	trauma	trauma	VERB
dpc-517	51	20	,	,	PUNCT
dpc-517	51	21	inflammation	inflammation	NOUN
dpc-517	51	22	,	,	PUNCT
dpc-517	51	23	surgery	surgery	NOUN
dpc-517	51	24	,	,	PUNCT
dpc-517	51	25	or	or	CCONJ
dpc-517	51	26	burns	burn	NOUN
dpc-517	51	27	and	and	CCONJ
dpc-517	51	28	extend	extend	VERB
dpc-517	51	29	beyond	beyond	ADP
dpc-517	51	30	the	the	DET
dpc-517	51	31	original	original	ADJ
dpc-517	51	32	defect	defect	NOUN
dpc-517	51	33	[	[	X
dpc-517	51	34	2	2	NUM
dpc-517	51	35	]	]	PUNCT
dpc-517	51	36	.	.	PUNCT
dpc-517	52	1	the	the	DET
dpc-517	52	2	uncontrolled	uncontrolled	ADJ
dpc-517	52	3	growth	growth	NOUN
dpc-517	52	4	of	of	ADP
dpc-517	52	5	keloids	keloid	NOUN
dpc-517	52	6	can	can	AUX
dpc-517	52	7	lead	lead	VERB
dpc-517	52	8	to	to	ADP
dpc-517	52	9	cosmetic	cosmetic	ADJ
dpc-517	52	10	disfigurement	disfigurement	NOUN
dpc-517	52	11	and	and	CCONJ
dpc-517	52	12	functional	functional	ADJ
dpc-517	52	13	impairment	impairment	NOUN
dpc-517	52	14	,	,	PUNCT
dpc-517	52	15	which	which	PRON
dpc-517	52	16	might	might	AUX
dpc-517	52	17	adversely	adversely	ADV
dpc-517	52	18	affect	affect	VERB
dpc-517	52	19	the	the	DET
dpc-517	52	20	quality	quality	NOUN
dpc-517	52	21	of	of	ADP
dpc-517	52	22	life	life	NOUN
dpc-517	52	23	[	[	X
dpc-517	52	24	3	3	NUM
dpc-517	52	25	]	]	PUNCT
dpc-517	52	26	.	.	PUNCT
dpc-517	53	1	a	a	DET
dpc-517	53	2	variety	variety	NOUN
dpc-517	53	3	of	of	ADP
dpc-517	53	4	treatment	treatment	NOUN
dpc-517	53	5	modalities	modality	NOUN
dpc-517	53	6	such	such	ADJ
dpc-517	53	7	as	as	ADP
dpc-517	53	8	silicone	silicone	NOUN
dpc-517	53	9	gel	gel	NOUN
dpc-517	53	10	sheeting	sheeting	NOUN
dpc-517	53	11	,	,	PUNCT
dpc-517	53	12	intralesional	intralesional	ADJ
dpc-517	53	13	injections	injection	NOUN
dpc-517	53	14	,	,	PUNCT
dpc-517	53	15	surgical	surgical	ADJ
dpc-517	53	16	manipulation	manipulation	NOUN
dpc-517	53	17	,	,	PUNCT
dpc-517	53	18	laser	laser	NOUN
dpc-517	53	19	,	,	PUNCT
dpc-517	53	20	and	and	CCONJ
dpc-517	53	21	radiotherapy	radiotherapy	NOUN
dpc-517	53	22	have	have	AUX
dpc-517	53	23	been	be	AUX
dpc-517	53	24	used	use	VERB
dpc-517	53	25	,	,	PUNCT
dpc-517	53	26	but	but	CCONJ
dpc-517	53	27	no	no	DET
dpc-517	53	28	particular	particular	ADJ
dpc-517	53	29	treatment	treatment	NOUN
dpc-517	53	30	has	have	AUX
dpc-517	53	31	been	be	AUX
dpc-517	53	32	shown	show	VERB
dpc-517	53	33	to	to	PART
dpc-517	53	34	be	be	AUX
dpc-517	53	35	effective	effective	ADJ
dpc-517	53	36	for	for	ADP
dpc-517	53	37	all	all	DET
dpc-517	53	38	cases	case	NOUN
dpc-517	53	39	[	[	X
dpc-517	53	40	4	4	NUM
dpc-517	53	41	]	]	PUNCT
dpc-517	53	42	.	.	PUNCT
dpc-517	54	1	drugs	drug	NOUN
dpc-517	54	2	like	like	ADP
dpc-517	54	3	bleomycin	bleomycin	NOUN
dpc-517	54	4	and	and	CCONJ
dpc-517	54	5	5	5	NUM
dpc-517	54	6	-	-	PUNCT
dpc-517	54	7	fluorouracil	fluorouracil	NOUN
dpc-517	54	8	have	have	VERB
dpc-517	54	9	better	well	ADJ
dpc-517	54	10	efficacy	efficacy	NOUN
dpc-517	54	11	,	,	PUNCT
dpc-517	54	12	but	but	CCONJ
dpc-517	54	13	they	they	PRON
dpc-517	54	14	are	be	AUX
dpc-517	54	15	costly	costly	ADJ
dpc-517	54	16	and	and	CCONJ
dpc-517	54	17	cause	cause	VERB
dpc-517	54	18	severe	severe	ADJ
dpc-517	54	19	drug	drug	NOUN
dpc-517	54	20	reactions	reaction	NOUN
dpc-517	54	21	.	.	PUNCT
dpc-517	55	1	surgery	surgery	NOUN
dpc-517	55	2	and	and	CCONJ
dpc-517	55	3	laser	laser	NOUN
dpc-517	55	4	therapy	therapy	NOUN
dpc-517	55	5	have	have	VERB
dpc-517	55	6	their	their	PRON
dpc-517	55	7	own	own	ADJ
dpc-517	55	8	limitations	limitation	NOUN
dpc-517	55	9	,	,	PUNCT
dpc-517	55	10	while	while	SCONJ
dpc-517	55	11	radiotherapy	radiotherapy	NOUN
dpc-517	55	12	can	can	AUX
dpc-517	55	13	cause	cause	VERB
dpc-517	55	14	malignancy	malignancy	NOUN
dpc-517	55	15	[	[	X
dpc-517	55	16	5	5	NUM
dpc-517	55	17	]	]	PUNCT
dpc-517	55	18	.	.	PUNCT
dpc-517	56	1	corticosteroids	corticosteroid	NOUN
dpc-517	56	2	seem	seem	VERB
dpc-517	56	3	to	to	PART
dpc-517	56	4	be	be	AUX
dpc-517	56	5	effective	effective	ADJ
dpc-517	56	6	in	in	ADP
dpc-517	56	7	the	the	DET
dpc-517	56	8	treatment	treatment	NOUN
dpc-517	56	9	of	of	ADP
dpc-517	56	10	keloids	keloid	NOUN
dpc-517	56	11	as	as	SCONJ
dpc-517	56	12	they	they	PRON
dpc-517	56	13	diminish	diminish	VERB
dpc-517	56	14	collagen	collagen	NOUN
dpc-517	56	15	and	and	CCONJ
dpc-517	56	16	glycosaminoglycan	glycosaminoglycan	ADJ
dpc-517	56	17	synthesis	synthesis	NOUN
dpc-517	56	18	,	,	PUNCT
dpc-517	56	19	inhibit	inhibit	VERB
dpc-517	56	20	fibroblast	fibroblast	ADJ
dpc-517	56	21	growth	growth	NOUN
dpc-517	56	22	,	,	PUNCT
dpc-517	56	23	enhance	enhance	VERB
dpc-517	56	24	collagen	collagen	NOUN
dpc-517	56	25	and	and	CCONJ
dpc-517	56	26	fibroblast	fibroblast	ADJ
dpc-517	56	27	degeneration	degeneration	NOUN
dpc-517	56	28	,	,	PUNCT
dpc-517	56	29	and	and	CCONJ
dpc-517	56	30	have	have	VERB
dpc-517	56	31	a	a	DET
dpc-517	56	32	powerful	powerful	ADJ
dpc-517	56	33	anti	anti	ADJ
dpc-517	56	34	-	-	ADJ
dpc-517	56	35	inflammatory	inflammatory	ADJ
dpc-517	56	36	effect	effect	NOUN
dpc-517	56	37	.	.	PUNCT
dpc-517	57	1	triamcinolone	triamcinolone	PROPN
dpc-517	57	2	acetonide	acetonide	NOUN
dpc-517	57	3	(	(	PUNCT
dpc-517	57	4	tac	tac	PROPN
dpc-517	57	5	)	)	PUNCT
dpc-517	57	6	is	be	AUX
dpc-517	57	7	the	the	DET
dpc-517	57	8	most	most	ADV
dpc-517	57	9	commonly	commonly	ADV
dpc-517	57	10	used	use	VERB
dpc-517	57	11	intralesional	intralesional	ADJ
dpc-517	57	12	corticosteroid	corticosteroid	NOUN
dpc-517	57	13	for	for	ADP
dpc-517	57	14	keloid	keloid	ADJ
dpc-517	57	15	treatment	treatment	NOUN
dpc-517	57	16	.	.	PUNCT
dpc-517	58	1	tac	tac	PROPN
dpc-517	58	2	is	be	AUX
dpc-517	58	3	cost	cost	NOUN
dpc-517	58	4	-	-	PUNCT
dpc-517	58	5	effective	effective	ADJ
dpc-517	58	6	and	and	CCONJ
dpc-517	58	7	practical	practical	ADJ
dpc-517	58	8	and	and	CCONJ
dpc-517	58	9	has	have	AUX
dpc-517	58	10	become	become	VERB
dpc-517	58	11	first	first	ADJ
dpc-517	58	12	-	-	PUNCT
dpc-517	58	13	line	line	NOUN
dpc-517	58	14	treatment	treatment	NOUN
dpc-517	58	15	for	for	ADP
dpc-517	58	16	keloids	keloid	NOUN
dpc-517	58	17	,	,	PUNCT
dpc-517	58	18	in	in	ADP
dpc-517	58	19	spite	spite	NOUN
dpc-517	58	20	of	of	ADP
dpc-517	58	21	some	some	DET
dpc-517	58	22	local	local	ADJ
dpc-517	58	23	adverse	adverse	ADJ
dpc-517	58	24	effects	effect	NOUN
dpc-517	58	25	such	such	ADJ
dpc-517	58	26	as	as	ADP
dpc-517	58	27	dermal	dermal	ADJ
dpc-517	58	28	atrophy	atrophy	NOUN
dpc-517	58	29	,	,	PUNCT
dpc-517	58	30	telangiectasia	telangiectasia	NOUN
dpc-517	58	31	,	,	PUNCT
dpc-517	58	32	and	and	CCONJ
dpc-517	58	33	hypopigmentation	hypopigmentation	NOUN
dpc-517	59	1	[	[	X
dpc-517	59	2	2	2	NUM
dpc-517	59	3	]	]	PUNCT
dpc-517	59	4	.	.	PUNCT
dpc-517	60	1	it	it	PRON
dpc-517	60	2	has	have	AUX
dpc-517	60	3	been	be	AUX
dpc-517	60	4	demonstrated	demonstrate	VERB
dpc-517	60	5	that	that	SCONJ
dpc-517	60	6	calcium	calcium	NOUN
dpc-517	60	7	channel	channel	NOUN
dpc-517	60	8	blockers	blocker	NOUN
dpc-517	60	9	decrease	decrease	VERB
dpc-517	60	10	extracellular	extracellular	ADJ
dpc-517	60	11	matrix	matrix	NOUN
dpc-517	60	12	production	production	NOUN
dpc-517	60	13	in	in	ADP
dpc-517	60	14	scars	scar	NOUN
dpc-517	60	15	.	.	PUNCT
dpc-517	61	1	furthermore	furthermore	ADV
dpc-517	61	2	,	,	PUNCT
dpc-517	61	3	they	they	PRON
dpc-517	61	4	depolymerize	depolymerize	VERB
dpc-517	61	5	actin	actin	NOUN
dpc-517	61	6	filaments	filament	NOUN
dpc-517	61	7	to	to	PART
dpc-517	61	8	modify	modify	VERB
dpc-517	61	9	fibroblast	fibroblast	ADJ
dpc-517	61	10	morphology	morphology	NOUN
dpc-517	61	11	by	by	ADP
dpc-517	61	12	a	a	DET
dpc-517	61	13	consequent	consequent	ADJ
dpc-517	61	14	increased	increase	VERB
dpc-517	61	15	secretion	secretion	NOUN
dpc-517	61	16	of	of	ADP
dpc-517	61	17	pro	pro	ADJ
dpc-517	61	18	-	-	ADJ
dpc-517	61	19	collagenase	collagenase	ADJ
dpc-517	61	20	[	[	X
dpc-517	61	21	6	6	NUM
dpc-517	61	22	]	]	PUNCT
dpc-517	61	23	.	.	PUNCT
dpc-517	62	1	intralesional	intralesional	ADJ
dpc-517	62	2	verapamil	verapamil	NOUN
dpc-517	62	3	hydrochloride	hydrochloride	NOUN
dpc-517	62	4	has	have	AUX
dpc-517	62	5	already	already	ADV
dpc-517	62	6	been	be	AUX
dpc-517	62	7	successfully	successfully	ADV
dpc-517	62	8	applied	apply	VERB
dpc-517	62	9	for	for	ADP
dpc-517	62	10	the	the	DET
dpc-517	62	11	treatment	treatment	NOUN
dpc-517	62	12	of	of	ADP
dpc-517	62	13	keloids	keloid	NOUN
dpc-517	62	14	[	[	X
dpc-517	62	15	7	7	NUM
dpc-517	62	16	]	]	PUNCT
dpc-517	62	17	.	.	PUNCT
dpc-517	63	1	this	this	DET
dpc-517	63	2	study	study	NOUN
dpc-517	63	3	was	be	AUX
dpc-517	63	4	hence	hence	ADV
dpc-517	63	5	conducted	conduct	VERB
dpc-517	63	6	to	to	PART
dpc-517	63	7	assess	assess	VERB
dpc-517	63	8	the	the	DET
dpc-517	63	9	efficacy	efficacy	NOUN
dpc-517	63	10	of	of	ADP
dpc-517	63	11	intralesional	intralesional	ADJ
dpc-517	63	12	verapamil	verapamil	NOUN
dpc-517	63	13	in	in	ADP
dpc-517	63	14	the	the	DET
dpc-517	63	15	treatment	treatment	NOUN
dpc-517	63	16	of	of	ADP
dpc-517	63	17	keloids	keloid	NOUN
dpc-517	63	18	by	by	ADP
dpc-517	63	19	its	its	PRON
dpc-517	63	20	comparison	comparison	NOUN
dpc-517	63	21	with	with	ADP
dpc-517	63	22	the	the	DET
dpc-517	63	23	effects	effect	NOUN
dpc-517	63	24	of	of	ADP
dpc-517	63	25	intralesional	intralesional	ADJ
dpc-517	63	26	triamcinolone	triamcinolone	NOUN
dpc-517	63	27	.	.	PUNCT
dpc-517	64	1	methods	method	NOUN
dpc-517	64	2	the	the	DET
dpc-517	64	3	study	study	NOUN
dpc-517	64	4	was	be	AUX
dpc-517	64	5	conducted	conduct	VERB
dpc-517	64	6	at	at	ADP
dpc-517	64	7	the	the	DET
dpc-517	64	8	department	department	NOUN
dpc-517	64	9	of	of	ADP
dpc-517	64	10	dermatology	dermatology	NOUN
dpc-517	64	11	,	,	PUNCT
dpc-517	64	12	faghihi	faghihi	PROPN
dpc-517	64	13	hospital	hospital	PROPN
dpc-517	64	14	,	,	PUNCT
dpc-517	64	15	shiraz	shiraz	PROPN
dpc-517	64	16	,	,	PUNCT
dpc-517	64	17	iran	iran	PROPN
dpc-517	64	18	,	,	PUNCT
dpc-517	64	19	from	from	ADP
dpc-517	64	20	december	december	PROPN
dpc-517	64	21	2017	2017	NUM
dpc-517	64	22	to	to	ADP
dpc-517	64	23	december	december	PROPN
dpc-517	64	24	2018	2018	NUM
dpc-517	64	25	.	.	PUNCT
dpc-517	65	1	this	this	DET
dpc-517	65	2	study	study	NOUN
dpc-517	65	3	was	be	AUX
dpc-517	65	4	approved	approve	VERB
dpc-517	65	5	by	by	ADP
dpc-517	65	6	the	the	DET
dpc-517	65	7	local	local	ADJ
dpc-517	65	8	ethics	ethic	NOUN
dpc-517	65	9	committee	committee	PROPN
dpc-517	65	10	of	of	ADP
dpc-517	65	11	shiraz	shiraz	PROPN
dpc-517	65	12	university	university	PROPN
dpc-517	65	13	of	of	ADP
dpc-517	65	14	medical	medical	ADJ
dpc-517	65	15	sciences	science	NOUN
dpc-517	65	16	and	and	CCONJ
dpc-517	65	17	registered	register	VERB
dpc-517	65	18	in	in	ADP
dpc-517	65	19	the	the	DET
dpc-517	65	20	iranian	iranian	ADJ
dpc-517	65	21	clinical	clinical	ADJ
dpc-517	65	22	trial	trial	NOUN
dpc-517	65	23	registry	registry	NOUN
dpc-517	65	24	.	.	PUNCT
dpc-517	66	1	all	all	DET
dpc-517	66	2	patients	patient	NOUN
dpc-517	66	3	signed	sign	VERB
dpc-517	66	4	the	the	DET
dpc-517	66	5	informed	informed	ADJ
dpc-517	66	6	consent	consent	NOUN
dpc-517	66	7	form	form	NOUN
dpc-517	66	8	prior	prior	ADV
dpc-517	66	9	to	to	ADP
dpc-517	66	10	initiation	initiation	NOUN
dpc-517	66	11	of	of	ADP
dpc-517	66	12	the	the	DET
dpc-517	66	13	trial	trial	NOUN
dpc-517	66	14	.	.	PUNCT
dpc-517	67	1	this	this	DET
dpc-517	67	2	study	study	NOUN
dpc-517	67	3	is	be	AUX
dpc-517	67	4	a	a	DET
dpc-517	67	5	randomized	randomized	ADJ
dpc-517	67	6	,	,	PUNCT
dpc-517	67	7	single	single	ADJ
dpc-517	67	8	-	-	PUNCT
dpc-517	67	9	group	group	NOUN
dpc-517	67	10	,	,	PUNCT
dpc-517	67	11	single	single	ADJ
dpc-517	67	12	-	-	PUNCT
dpc-517	67	13	blind	blind	ADJ
dpc-517	67	14	comparison	comparison	NOUN
dpc-517	67	15	between	between	ADP
dpc-517	67	16	triamcinolone	triamcinolone	NOUN
dpc-517	67	17	and	and	CCONJ
dpc-517	67	18	verapamil	verapamil	NOUN
dpc-517	67	19	injection	injection	NOUN
dpc-517	67	20	.	.	PUNCT
dpc-517	68	1	inclusion	inclusion	NOUN
dpc-517	68	2	criteria	criterion	NOUN
dpc-517	68	3	involved	involve	VERB
dpc-517	68	4	patients	patient	NOUN
dpc-517	68	5	aged	age	VERB
dpc-517	68	6	between	between	ADP
dpc-517	68	7	18	18	NUM
dpc-517	68	8	and	and	CCONJ
dpc-517	68	9	70	70	NUM
dpc-517	68	10	years	year	NOUN
dpc-517	68	11	old	old	ADJ
dpc-517	68	12	,	,	PUNCT
dpc-517	68	13	with	with	ADP
dpc-517	68	14	at	at	ADV
dpc-517	68	15	least	least	ADJ
dpc-517	68	16	2	2	NUM
dpc-517	68	17	scars	scar	NOUN
dpc-517	68	18	with	with	ADP
dpc-517	68	19	duration	duration	NOUN
dpc-517	68	20	of	of	ADP
dpc-517	68	21	less	less	ADJ
dpc-517	68	22	than	than	ADP
dpc-517	68	23	2	2	NUM
dpc-517	68	24	years	year	NOUN
dpc-517	68	25	.	.	PUNCT
dpc-517	69	1	patients	patient	NOUN
dpc-517	69	2	with	with	ADP
dpc-517	69	3	evidence	evidence	NOUN
dpc-517	69	4	of	of	ADP
dpc-517	69	5	any	any	DET
dpc-517	69	6	infection	infection	NOUN
dpc-517	69	7	(	(	PUNCT
dpc-517	69	8	in	in	ADP
dpc-517	69	9	or	or	CCONJ
dpc-517	69	10	near	near	ADP
dpc-517	69	11	the	the	DET
dpc-517	69	12	scar	scar	NOUN
dpc-517	69	13	area	area	NOUN
dpc-517	69	14	)	)	PUNCT
dpc-517	69	15	,	,	PUNCT
dpc-517	69	16	those	those	PRON
dpc-517	69	17	with	with	ADP
dpc-517	69	18	a	a	DET
dpc-517	69	19	history	history	NOUN
dpc-517	69	20	of	of	ADP
dpc-517	69	21	cardiovascular	cardiovascular	ADJ
dpc-517	69	22	problems	problem	NOUN
dpc-517	69	23	,	,	PUNCT
dpc-517	69	24	pregnant	pregnant	ADJ
dpc-517	69	25	women	woman	NOUN
dpc-517	69	26	,	,	PUNCT
dpc-517	69	27	and	and	CCONJ
dpc-517	69	28	patients	patient	NOUN
dpc-517	69	29	with	with	ADP
dpc-517	69	30	a	a	DET
dpc-517	69	31	history	history	NOUN
dpc-517	69	32	6	6	NUM
dpc-517	69	33	research	research	NOUN
dpc-517	69	34	|	|	ADV
dpc-517	69	35	dermatol	dermatol	NOUN
dpc-517	69	36	pract	pract	PROPN
dpc-517	69	37	concept	concept	NOUN
dpc-517	69	38	2019;9(1):2	2019;9(1):2	PROPN
dpc-517	69	39	figures	figure	NOUN
dpc-517	69	40	2	2	NUM
dpc-517	69	41	and	and	CCONJ
dpc-517	69	42	3	3	NUM
dpc-517	69	43	represent	represent	VERB
dpc-517	69	44	the	the	DET
dpc-517	69	45	beforeafter	beforeafter	NOUN
dpc-517	69	46	photographs	photograph	NOUN
dpc-517	69	47	of	of	ADP
dpc-517	69	48	a	a	DET
dpc-517	69	49	patient	patient	NOUN
dpc-517	69	50	in	in	ADP
dpc-517	69	51	the	the	DET
dpc-517	69	52	triamcinolone	triamcinolone	NOUN
dpc-517	69	53	and	and	CCONJ
dpc-517	69	54	verapamil	verapamil	NOUN
dpc-517	69	55	groups	group	NOUN
dpc-517	69	56	,	,	PUNCT
dpc-517	69	57	respectively	respectively	ADV
dpc-517	69	58	.	.	PUNCT
dpc-517	70	1	discussion	discussion	NOUN
dpc-517	70	2	despite	despite	SCONJ
dpc-517	70	3	numerous	numerous	ADJ
dpc-517	70	4	developed	developed	ADJ
dpc-517	70	5	therapies	therapy	NOUN
dpc-517	70	6	,	,	PUNCT
dpc-517	70	7	keloid	keloid	ADJ
dpc-517	70	8	treatment	treatment	NOUN
dpc-517	70	9	has	have	AUX
dpc-517	70	10	remained	remain	VERB
dpc-517	70	11	a	a	DET
dpc-517	70	12	challenging	challenging	ADJ
dpc-517	70	13	clinical	clinical	ADJ
dpc-517	70	14	problem	problem	NOUN
dpc-517	70	15	.	.	PUNCT
dpc-517	71	1	this	this	PRON
dpc-517	71	2	might	might	AUX
dpc-517	71	3	be	be	AUX
dpc-517	71	4	due	due	ADJ
dpc-517	71	5	to	to	ADP
dpc-517	71	6	the	the	DET
dpc-517	71	7	fact	fact	NOUN
dpc-517	71	8	that	that	SCONJ
dpc-517	71	9	the	the	DET
dpc-517	71	10	mechanisms	mechanism	NOUN
dpc-517	71	11	of	of	ADP
dpc-517	71	12	development	development	NOUN
dpc-517	71	13	of	of	ADP
dpc-517	71	14	keloids	keloid	NOUN
dpc-517	71	15	have	have	AUX
dpc-517	71	16	not	not	PART
dpc-517	71	17	been	be	AUX
dpc-517	71	18	completely	completely	ADV
dpc-517	71	19	understood	understand	VERB
dpc-517	71	20	[	[	PUNCT
dpc-517	71	21	9	9	NUM
dpc-517	71	22	]	]	PUNCT
dpc-517	71	23	.	.	PUNCT
dpc-517	72	1	laser	laser	NOUN
dpc-517	72	2	therapy	therapy	NOUN
dpc-517	72	3	,	,	PUNCT
dpc-517	72	4	surgical	surgical	ADJ
dpc-517	72	5	removal	removal	NOUN
dpc-517	72	6	,	,	PUNCT
dpc-517	72	7	radiation	radiation	NOUN
dpc-517	72	8	therapy	therapy	NOUN
dpc-517	72	9	,	,	PUNCT
dpc-517	72	10	silicone	silicone	NOUN
dpc-517	72	11	gel	gel	NOUN
dpc-517	72	12	,	,	PUNCT
dpc-517	72	13	cryosurgery	cryosurgery	NOUN
dpc-517	72	14	,	,	PUNCT
dpc-517	72	15	intralesional	intralesional	ADJ
dpc-517	72	16	injection	injection	NOUN
dpc-517	72	17	of	of	ADP
dpc-517	72	18	various	various	ADJ
dpc-517	72	19	agents	agent	NOUN
dpc-517	72	20	,	,	PUNCT
dpc-517	72	21	and	and	CCONJ
dpc-517	72	22	occlusive	occlusive	NOUN
dpc-517	72	23	dressing	dressing	NOUN
dpc-517	72	24	have	have	AUX
dpc-517	72	25	all	all	PRON
dpc-517	72	26	been	be	AUX
dpc-517	72	27	used	use	VERB
dpc-517	72	28	either	either	CCONJ
dpc-517	72	29	alone	alone	ADJ
dpc-517	72	30	or	or	CCONJ
dpc-517	72	31	in	in	ADP
dpc-517	72	32	various	various	ADJ
dpc-517	72	33	combinations	combination	NOUN
dpc-517	72	34	[	[	X
dpc-517	72	35	10	10	NUM
dpc-517	72	36	]	]	PUNCT
dpc-517	72	37	.	.	PUNCT
dpc-517	73	1	however	however	ADV
dpc-517	73	2	,	,	PUNCT
dpc-517	73	3	evolution	evolution	NOUN
dpc-517	73	4	of	of	ADP
dpc-517	73	5	different	different	ADJ
dpc-517	73	6	therapies	therapy	NOUN
dpc-517	73	7	has	have	AUX
dpc-517	73	8	not	not	PART
dpc-517	73	9	significantly	significantly	ADV
dpc-517	73	10	improved	improve	VERB
dpc-517	73	11	their	their	PRON
dpc-517	73	12	success	success	NOUN
dpc-517	73	13	rates	rate	NOUN
dpc-517	73	14	.	.	PUNCT
dpc-517	74	1	in	in	ADP
dpc-517	74	2	addition	addition	NOUN
dpc-517	74	3	,	,	PUNCT
dpc-517	74	4	each	each	DET
dpc-517	74	5	method	method	NOUN
dpc-517	74	6	has	have	VERB
dpc-517	74	7	its	its	PRON
dpc-517	74	8	own	own	ADJ
dpc-517	74	9	limitations	limitation	NOUN
dpc-517	74	10	such	such	ADJ
dpc-517	74	11	as	as	ADP
dpc-517	74	12	high	high	ADJ
dpc-517	74	13	cost	cost	NOUN
dpc-517	74	14	,	,	PUNCT
dpc-517	74	15	poor	poor	ADJ
dpc-517	74	16	efficacy	efficacy	NOUN
dpc-517	74	17	,	,	PUNCT
dpc-517	74	18	recurrence	recurrence	NOUN
dpc-517	74	19	,	,	PUNCT
dpc-517	74	20	and	and	CCONJ
dpc-517	74	21	adverse	adverse	ADJ
dpc-517	74	22	effects	effect	NOUN
dpc-517	74	23	(	(	PUNCT
dpc-517	74	24	such	such	ADJ
dpc-517	74	25	as	as	ADP
dpc-517	74	26	malignancy	malignancy	NOUN
dpc-517	74	27	)	)	PUNCT
dpc-517	74	28	.	.	PUNCT
dpc-517	75	1	the	the	DET
dpc-517	75	2	vss	vss	NOUN
dpc-517	75	3	parameters	parameter	NOUN
dpc-517	75	4	for	for	ADP
dpc-517	75	5	both	both	DET
dpc-517	75	6	treatment	treatment	NOUN
dpc-517	75	7	groups	group	NOUN
dpc-517	75	8	are	be	AUX
dpc-517	75	9	presented	present	VERB
dpc-517	75	10	in	in	ADP
dpc-517	75	11	table	table	NOUN
dpc-517	75	12	1	1	NUM
dpc-517	75	13	.	.	PUNCT
dpc-517	76	1	at	at	ADP
dpc-517	76	2	the	the	DET
dpc-517	76	3	beginning	beginning	NOUN
dpc-517	76	4	of	of	ADP
dpc-517	76	5	the	the	DET
dpc-517	76	6	study	study	NOUN
dpc-517	76	7	,	,	PUNCT
dpc-517	76	8	there	there	PRON
dpc-517	76	9	was	be	VERB
dpc-517	76	10	no	no	DET
dpc-517	76	11	significant	significant	ADJ
dpc-517	76	12	difference	difference	NOUN
dpc-517	76	13	in	in	ADP
dpc-517	76	14	parameters	parameter	NOUN
dpc-517	76	15	of	of	ADP
dpc-517	76	16	the	the	DET
dpc-517	76	17	2	2	NUM
dpc-517	76	18	groups	group	NOUN
dpc-517	76	19	(	(	PUNCT
dpc-517	76	20	p	p	X
dpc-517	76	21	>	>	X
dpc-517	76	22	0.05	0.05	NUM
dpc-517	76	23	)	)	PUNCT
dpc-517	76	24	.	.	PUNCT
dpc-517	77	1	in	in	ADP
dpc-517	77	2	both	both	DET
dpc-517	77	3	study	study	NOUN
dpc-517	77	4	groups	group	NOUN
dpc-517	77	5	,	,	PUNCT
dpc-517	77	6	there	there	PRON
dpc-517	77	7	was	be	VERB
dpc-517	77	8	a	a	DET
dpc-517	77	9	reduction	reduction	NOUN
dpc-517	77	10	in	in	ADP
dpc-517	77	11	height	height	NOUN
dpc-517	77	12	and	and	CCONJ
dpc-517	77	13	pliability	pliability	NOUN
dpc-517	77	14	at	at	ADP
dpc-517	77	15	the	the	DET
dpc-517	77	16	end	end	NOUN
dpc-517	77	17	of	of	ADP
dpc-517	77	18	the	the	DET
dpc-517	77	19	study	study	NOUN
dpc-517	77	20	as	as	SCONJ
dpc-517	77	21	determined	determine	VERB
dpc-517	77	22	by	by	ADP
dpc-517	77	23	wilcoxon	wilcoxon	ADJ
dpc-517	77	24	test	test	PROPN
dpc-517	77	25	(	(	PUNCT
dpc-517	77	26	table	table	NOUN
dpc-517	77	27	2	2	NUM
dpc-517	77	28	)	)	PUNCT
dpc-517	77	29	.	.	PUNCT
dpc-517	78	1	using	use	VERB
dpc-517	78	2	mann	mann	PROPN
dpc-517	78	3	-	-	PUNCT
dpc-517	78	4	whitney	whitney	PROPN
dpc-517	78	5	u	u	PROPN
dpc-517	78	6	test	test	NOUN
dpc-517	78	7	,	,	PUNCT
dpc-517	78	8	statistically	statistically	ADV
dpc-517	78	9	better	well	ADJ
dpc-517	78	10	improvement	improvement	NOUN
dpc-517	78	11	in	in	ADP
dpc-517	78	12	height	height	NOUN
dpc-517	78	13	and	and	CCONJ
dpc-517	78	14	pliability	pliability	NOUN
dpc-517	78	15	was	be	AUX
dpc-517	78	16	observed	observe	VERB
dpc-517	78	17	in	in	ADP
dpc-517	78	18	the	the	DET
dpc-517	78	19	triamcinolone	triamcinolone	NOUN
dpc-517	78	20	-	-	PUNCT
dpc-517	78	21	receiving	receive	VERB
dpc-517	78	22	group	group	NOUN
dpc-517	78	23	compared	compare	VERB
dpc-517	78	24	with	with	ADP
dpc-517	78	25	the	the	DET
dpc-517	78	26	verapamil	verapamil	NOUN
dpc-517	78	27	-	-	PUNCT
dpc-517	78	28	receiving	receive	VERB
dpc-517	78	29	group	group	NOUN
dpc-517	78	30	(	(	PUNCT
dpc-517	78	31	p	p	X
dpc-517	78	32	<	<	X
dpc-517	78	33	0.001	0.001	NUM
dpc-517	78	34	)	)	PUNCT
dpc-517	78	35	.	.	PUNCT
dpc-517	79	1	however	however	ADV
dpc-517	79	2	,	,	PUNCT
dpc-517	79	3	a	a	DET
dpc-517	79	4	desired	desire	VERB
dpc-517	79	5	change	change	NOUN
dpc-517	79	6	in	in	ADP
dpc-517	79	7	vascularity	vascularity	NOUN
dpc-517	79	8	and	and	CCONJ
dpc-517	79	9	pigmentation	pigmentation	NOUN
dpc-517	79	10	was	be	AUX
dpc-517	79	11	not	not	PART
dpc-517	79	12	seen	see	VERB
dpc-517	79	13	with	with	ADP
dpc-517	79	14	either	either	PRON
dpc-517	79	15	of	of	ADP
dpc-517	79	16	the	the	DET
dpc-517	79	17	drugs	drug	NOUN
dpc-517	79	18	(	(	PUNCT
dpc-517	79	19	table	table	NOUN
dpc-517	79	20	2	2	NUM
dpc-517	79	21	)	)	PUNCT
dpc-517	79	22	.	.	PUNCT
dpc-517	80	1	scar	scar	ADJ
dpc-517	80	2	vascularity	vascularity	NOUN
dpc-517	80	3	became	become	VERB
dpc-517	80	4	worse	bad	ADJ
dpc-517	80	5	in	in	ADP
dpc-517	80	6	1	1	NUM
dpc-517	80	7	out	out	ADP
dpc-517	80	8	of	of	ADP
dpc-517	80	9	15	15	NUM
dpc-517	80	10	scars	scar	NOUN
dpc-517	80	11	in	in	ADP
dpc-517	80	12	the	the	DET
dpc-517	80	13	triamcinolone	triamcinolone	NOUN
dpc-517	80	14	group	group	NOUN
dpc-517	80	15	.	.	PUNCT
dpc-517	81	1	it	it	PRON
dpc-517	81	2	can	can	AUX
dpc-517	81	3	be	be	AUX
dpc-517	81	4	observed	observe	VERB
dpc-517	81	5	that	that	SCONJ
dpc-517	81	6	12	12	NUM
dpc-517	81	7	out	out	ADP
dpc-517	81	8	of	of	ADP
dpc-517	81	9	15	15	NUM
dpc-517	81	10	scars	scar	NOUN
dpc-517	81	11	in	in	ADP
dpc-517	81	12	both	both	DET
dpc-517	81	13	groups	group	NOUN
dpc-517	81	14	had	have	VERB
dpc-517	81	15	normal	normal	ADJ
dpc-517	81	16	pigmentation	pigmentation	NOUN
dpc-517	81	17	at	at	ADP
dpc-517	81	18	the	the	DET
dpc-517	81	19	start	start	NOUN
dpc-517	81	20	of	of	ADP
dpc-517	81	21	the	the	DET
dpc-517	81	22	study	study	NOUN
dpc-517	81	23	.	.	PUNCT
dpc-517	82	1	after	after	ADP
dpc-517	82	2	24	24	NUM
dpc-517	82	3	weeks	week	NOUN
dpc-517	82	4	,	,	PUNCT
dpc-517	82	5	1	1	NUM
dpc-517	82	6	out	out	ADP
dpc-517	82	7	of	of	ADP
dpc-517	82	8	3	3	NUM
dpc-517	82	9	hyperpigmented	hyperpigmented	ADJ
dpc-517	82	10	scars	scar	NOUN
dpc-517	82	11	in	in	ADP
dpc-517	82	12	the	the	DET
dpc-517	82	13	verapamil	verapamil	NOUN
dpc-517	82	14	group	group	NOUN
dpc-517	82	15	regained	regain	VERB
dpc-517	82	16	normal	normal	ADJ
dpc-517	82	17	pigmentation	pigmentation	NOUN
dpc-517	82	18	while	while	SCONJ
dpc-517	82	19	the	the	DET
dpc-517	82	20	other	other	ADJ
dpc-517	82	21	2	2	NUM
dpc-517	82	22	scars	scar	NOUN
dpc-517	82	23	remained	remain	VERB
dpc-517	82	24	hyperpigmented	hyperpigmente	VERB
dpc-517	82	25	.	.	PUNCT
dpc-517	83	1	however	however	ADV
dpc-517	83	2	,	,	PUNCT
dpc-517	83	3	out	out	ADP
dpc-517	83	4	of	of	ADP
dpc-517	83	5	3	3	NUM
dpc-517	83	6	hyperpigmented	hyperpigmented	ADJ
dpc-517	83	7	scars	scar	NOUN
dpc-517	83	8	in	in	ADP
dpc-517	83	9	the	the	DET
dpc-517	83	10	triamcinolone	triamcinolone	NOUN
dpc-517	83	11	group	group	NOUN
dpc-517	83	12	,	,	PUNCT
dpc-517	83	13	1	1	NUM
dpc-517	83	14	regained	regain	VERB
dpc-517	83	15	normal	normal	ADJ
dpc-517	83	16	pigmentation	pigmentation	NOUN
dpc-517	83	17	while	while	SCONJ
dpc-517	83	18	the	the	DET
dpc-517	83	19	other	other	ADJ
dpc-517	83	20	2	2	NUM
dpc-517	83	21	scars	scar	NOUN
dpc-517	83	22	became	become	VERB
dpc-517	83	23	hypopigmented	hypopigmente	VERB
dpc-517	83	24	at	at	ADP
dpc-517	83	25	the	the	DET
dpc-517	83	26	end	end	NOUN
dpc-517	83	27	of	of	ADP
dpc-517	83	28	our	our	PRON
dpc-517	83	29	trial	trial	NOUN
dpc-517	83	30	(	(	PUNCT
dpc-517	83	31	table	table	NOUN
dpc-517	83	32	3	3	NUM
dpc-517	83	33	)	)	PUNCT
dpc-517	83	34	.	.	PUNCT
dpc-517	84	1	no	no	DET
dpc-517	84	2	significant	significant	ADJ
dpc-517	84	3	difference	difference	NOUN
dpc-517	84	4	was	be	AUX
dpc-517	84	5	detected	detect	VERB
dpc-517	84	6	in	in	ADP
dpc-517	84	7	vascularity	vascularity	NOUN
dpc-517	84	8	and	and	CCONJ
dpc-517	84	9	pigmentation	pigmentation	NOUN
dpc-517	84	10	in	in	ADP
dpc-517	84	11	the	the	DET
dpc-517	84	12	2	2	NUM
dpc-517	84	13	groups	group	NOUN
dpc-517	84	14	(	(	PUNCT
dpc-517	84	15	p	p	X
dpc-517	84	16	>	>	X
dpc-517	84	17	0.05	0.05	NUM
dpc-517	84	18	)	)	PUNCT
dpc-517	84	19	.	.	PUNCT
dpc-517	85	1	the	the	DET
dpc-517	85	2	changes	change	NOUN
dpc-517	85	3	in	in	ADP
dpc-517	85	4	vss	vss	NOUN
dpc-517	85	5	score	score	NOUN
dpc-517	85	6	parameters	parameter	NOUN
dpc-517	85	7	within	within	ADP
dpc-517	85	8	24	24	NUM
dpc-517	85	9	weeks	week	NOUN
dpc-517	85	10	of	of	ADP
dpc-517	85	11	follow	follow	NOUN
dpc-517	85	12	-	-	PUNCT
dpc-517	85	13	up	up	NOUN
dpc-517	85	14	in	in	ADP
dpc-517	85	15	both	both	DET
dpc-517	85	16	groups	group	NOUN
dpc-517	85	17	are	be	AUX
dpc-517	85	18	shown	show	VERB
dpc-517	85	19	in	in	ADP
dpc-517	85	20	figure1	figure1	PROPN
dpc-517	85	21	.	.	PUNCT
dpc-517	86	1	table	table	NOUN
dpc-517	86	2	1	1	NUM
dpc-517	86	3	.	.	PUNCT
dpc-517	87	1	mean	mean	PROPN
dpc-517	87	2	vss	vss	NOUN
dpc-517	87	3	scores	score	NOUN
dpc-517	87	4	during	during	ADP
dpc-517	87	5	24	24	NUM
dpc-517	87	6	weeks	week	NOUN
dpc-517	87	7	of	of	ADP
dpc-517	87	8	follow	follow	VERB
dpc-517	87	9	-	-	PUNCT
dpc-517	87	10	up	up	ADP
dpc-517	87	11	intralesional	intralesional	ADJ
dpc-517	87	12	injection	injection	NOUN
dpc-517	87	13	interval	interval	NOUN
dpc-517	87	14	in	in	ADP
dpc-517	87	15	weeks	week	NOUN
dpc-517	87	16	with	with	ADP
dpc-517	87	17	mean	mean	PROPN
dpc-517	87	18	vss	vss	NOUN
dpc-517	87	19	scores	score	NOUN
dpc-517	87	20	±	±	PROPN
dpc-517	87	21	sd	sd	PROPN
dpc-517	87	22	vss	vss	NOUN
dpc-517	87	23	parameters	parameter	NOUN
dpc-517	87	24	drug	drug	VERB
dpc-517	87	25	0	0	PROPN
dpc-517	87	26	wks	wks	PROPN
dpc-517	87	27	3	3	NUM
dpc-517	87	28	wks	wks	NOUN
dpc-517	87	29	6	6	NUM
dpc-517	87	30	wks	wks	NOUN
dpc-517	87	31	9	9	NUM
dpc-517	87	32	wks	wks	NOUN
dpc-517	87	33	12	12	NUM
dpc-517	87	34	wks	wks	NOUN
dpc-517	87	35	15	15	NUM
dpc-517	87	36	wks	wks	NOUN
dpc-517	87	37	18	18	NUM
dpc-517	87	38	wks	wk	NOUN
dpc-517	87	39	21	21	NUM
dpc-517	87	40	wks	wks	NOUN
dpc-517	87	41	24	24	NUM
dpc-517	87	42	wks	wks	NOUN
dpc-517	87	43	height	height	NOUN
dpc-517	87	44	v	v	ADP
dpc-517	87	45	4.11±1.90	4.11±1.90	PROPN
dpc-517	87	46	4.11±1.90	4.11±1.90	NOUN
dpc-517	87	47	4.04±1.92	4.04±1.92	NOUN
dpc-517	88	1	3.90±1.95	3.90±1.95	NUM
dpc-517	88	2	3.77±1.94	3.77±1.94	NUM
dpc-517	88	3	3.77±1.94	3.77±1.94	NUM
dpc-517	88	4	3.71±1.99	3.71±1.99	NOUN
dpc-517	88	5	3.43±2.04	3.43±2.04	NUM
dpc-517	88	6	3.10±1.85	3.10±1.85	NUM
dpc-517	88	7	t	t	NOUN
dpc-517	88	8	4.25±1.94	4.25±1.94	NUM
dpc-517	88	9	3.98±1.92	3.98±1.92	NUM
dpc-517	88	10	2.97±2.07	2.97±2.07	NUM
dpc-517	88	11	1.97±2.06	1.97±2.06	NUM
dpc-517	88	12	1.16±1.91	1.16±1.91	NUM
dpc-517	88	13	0.82±1.95	0.82±1.95	NOUN
dpc-517	88	14	0.55±1.12	0.55±1.12	PROPN
dpc-517	88	15	0.34±0.90	0.34±0.90	NOUN
dpc-517	88	16	0.21±0.56	0.21±0.56	NOUN
dpc-517	88	17	vascularity	vascularity	NOUN
dpc-517	88	18	v	v	ADP
dpc-517	88	19	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	20	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	21	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	22	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	23	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	24	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	25	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	26	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	27	0.87±0.74	0.87±0.74	PROPN
dpc-517	88	28	t	t	PROPN
dpc-517	88	29	0.87±0.74	0.87±0.74	PROPN
dpc-517	89	1	0.93±0.70	0.93±0.70	PRON
dpc-517	90	1	0.93±0.70	0.93±0.70	X
dpc-517	91	1	0.93±0.70	0.93±0.70	INTJ
dpc-517	92	1	0.93±0.70	0.93±0.70	INTJ
dpc-517	93	1	0.93±0.70	0.93±0.70	INTJ
dpc-517	94	1	0.93±0.70	0.93±0.70	PRON
dpc-517	95	1	0.93±0.70	0.93±0.70	PRON
dpc-517	95	2	0.93±0.70	0.93±0.70	NUM
dpc-517	95	3	pliability	pliability	NOUN
dpc-517	95	4	v	v	ADP
dpc-517	95	5	2.87±0.35	2.87±0.35	NUM
dpc-517	95	6	2.87±0.35	2.87±0.35	NUM
dpc-517	95	7	2.87±0.35	2.87±0.35	NUM
dpc-517	95	8	2.80±0.41	2.80±0.41	NOUN
dpc-517	95	9	2.73±0.46	2.73±0.46	NUM
dpc-517	95	10	2.73±0.46	2.73±0.46	PROPN
dpc-517	96	1	2.60±0.51	2.60±0.51	PROPN
dpc-517	96	2	2.27±0.46	2.27±0.46	PROPN
dpc-517	96	3	2.07±0.26	2.07±0.26	ADJ
dpc-517	96	4	t	t	NOUN
dpc-517	96	5	2.87±0.35	2.87±0.35	NUM
dpc-517	96	6	2.73±0.46	2.73±0.46	NUM
dpc-517	96	7	1.93±0.70	1.93±0.70	NUM
dpc-517	96	8	1.20±1.01	1.20±1.01	NUM
dpc-517	96	9	0.67±0.90	0.67±0.90	NOUN
dpc-517	96	10	0.47±0.83	0.47±0.83	ADJ
dpc-517	96	11	0.47±0.83	0.47±0.83	ADJ
dpc-517	96	12	0.27±0.59	0.27±0.59	VERB
dpc-517	96	13	0.20±0.41	0.20±0.41	ADJ
dpc-517	96	14	pigmentation	pigmentation	NOUN
dpc-517	96	15	v	v	ADP
dpc-517	96	16	0.40±0.83	0.40±0.83	PROPN
dpc-517	96	17	0.40±0.83	0.40±0.83	PROPN
dpc-517	96	18	0.40±0.83	0.40±0.83	NOUN
dpc-517	96	19	0.40±0.83	0.40±0.83	NOUN
dpc-517	96	20	0.40±0.83	0.40±0.83	NOUN
dpc-517	96	21	0.40±0.83	0.40±0.83	PROPN
dpc-517	96	22	0.40±0.83	0.40±0.83	PROPN
dpc-517	97	1	0.27±0.70	0.27±0.70	NOUN
dpc-517	98	1	0.27±0.70	0.27±0.70	INTJ
dpc-517	98	2	t	t	NOUN
dpc-517	98	3	0.40±0.83	0.40±0.83	PROPN
dpc-517	98	4	0.40±0.83	0.40±0.83	PROPN
dpc-517	98	5	0.20±0.56	0.20±0.56	NOUN
dpc-517	98	6	0.13±0.35	0.13±0.35	NOUN
dpc-517	98	7	0.13±0.35	0.13±0.35	NOUN
dpc-517	98	8	0.13±0.35	0.13±0.35	NOUN
dpc-517	98	9	0.13±0.35	0.13±0.35	NOUN
dpc-517	98	10	0.13±0.35	0.13±0.35	NOUN
dpc-517	98	11	0.13±0.35	0.13±0.35	NOUN
dpc-517	98	12	wks	wks	NOUN
dpc-517	98	13	=	=	NOUN
dpc-517	98	14	weeks	week	NOUN
dpc-517	98	15	;	;	PUNCT
dpc-517	98	16	v	v	NOUN
dpc-517	98	17	=	=	SYM
dpc-517	98	18	verapamil	verapamil	NOUN
dpc-517	98	19	;	;	PUNCT
dpc-517	98	20	t	t	NOUN
dpc-517	98	21	=	=	PUNCT
dpc-517	98	22	triamcinolone	triamcinolone	NOUN
dpc-517	98	23	;	;	PUNCT
dpc-517	98	24	sd	sd	NOUN
dpc-517	98	25	=	=	PUNCT
dpc-517	98	26	standard	standard	ADJ
dpc-517	98	27	deviation	deviation	NOUN
dpc-517	98	28	.	.	PUNCT
dpc-517	99	1	table	table	NOUN
dpc-517	99	2	2	2	NUM
dpc-517	99	3	.	.	PUNCT
dpc-517	100	1	mean	mean	PROPN
dpc-517	100	2	vss	vss	NOUN
dpc-517	100	3	scores	score	NOUN
dpc-517	100	4	±	±	NOUN
dpc-517	100	5	sd	sd	ADP
dpc-517	100	6	before	before	ADV
dpc-517	100	7	and	and	CCONJ
dpc-517	100	8	after	after	ADP
dpc-517	100	9	treatment	treatment	NOUN
dpc-517	100	10	in	in	ADP
dpc-517	100	11	triamcinolone	triamcinolone	NOUN
dpc-517	100	12	and	and	CCONJ
dpc-517	100	13	verapamil	verapamil	NOUN
dpc-517	100	14	groups	group	NOUN
dpc-517	100	15	vss	vss	VERB
dpc-517	100	16	parameters	parameter	NOUN
dpc-517	100	17	drug	drug	PROPN
dpc-517	100	18	week	week	NOUN
dpc-517	100	19	0	0	NUM
dpc-517	100	20	week	week	NOUN
dpc-517	101	1	24	24	NUM
dpc-517	101	2	p	p	NOUN
dpc-517	101	3	value	value	NOUN
dpc-517	101	4	height	height	NOUN
dpc-517	101	5	v	v	ADP
dpc-517	101	6	4.11±1.90	4.11±1.90	PROPN
dpc-517	102	1	3.10±1.85	3.10±1.85	NOUN
dpc-517	102	2	<	<	X
dpc-517	102	3	0.001	0.001	NUM
dpc-517	102	4	t	t	NOUN
dpc-517	102	5	4.25±1.94	4.25±1.94	PROPN
dpc-517	102	6	0.21±0.56	0.21±0.56	NOUN
dpc-517	102	7	<	<	NOUN
dpc-517	102	8	0.001	0.001	NUM
dpc-517	102	9	vascularity	vascularity	NOUN
dpc-517	102	10	v	v	ADP
dpc-517	102	11	0.87±0.74	0.87±0.74	VERB
dpc-517	102	12	0.87±0.74	0.87±0.74	ADJ
dpc-517	102	13	1	1	NUM
dpc-517	102	14	t	t	NOUN
dpc-517	102	15	0.87±0.74	0.87±0.74	NOUN
dpc-517	102	16	0.93±0.70	0.93±0.70	PRON
dpc-517	102	17	0.32	0.32	NUM
dpc-517	102	18	pliability	pliability	NOUN
dpc-517	102	19	v	v	ADP
dpc-517	102	20	2.87±0.35	2.87±0.35	NUM
dpc-517	102	21	2.07±0.26	2.07±0.26	NOUN
dpc-517	102	22	<	<	X
dpc-517	102	23	0.001	0.001	NUM
dpc-517	102	24	t	t	NOUN
dpc-517	102	25	2.87±0.35	2.87±0.35	NUM
dpc-517	102	26	0.20±0.41	0.20±0.41	ADJ
dpc-517	102	27	<	<	X
dpc-517	102	28	0.001	0.001	NUM
dpc-517	102	29	pigmentation	pigmentation	NOUN
dpc-517	102	30	v	v	ADP
dpc-517	102	31	0.40±0.83	0.40±0.83	PROPN
dpc-517	102	32	0.27±0.70	0.27±0.70	NOUN
dpc-517	102	33	0.32	0.32	NUM
dpc-517	102	34	t	t	NOUN
dpc-517	102	35	0.40±0.83	0.40±0.83	PROPN
dpc-517	102	36	0.13±0.35	0.13±0.35	NOUN
dpc-517	102	37	0.10	0.10	NUM
dpc-517	102	38	v	v	NOUN
dpc-517	102	39	=	=	SYM
dpc-517	102	40	verapamil	verapamil	NOUN
dpc-517	102	41	;	;	PUNCT
dpc-517	102	42	t	t	NOUN
dpc-517	102	43	=	=	PUNCT
dpc-517	102	44	triamcinolone	triamcinolone	NOUN
dpc-517	102	45	;	;	PUNCT
dpc-517	102	46	sd	sd	NOUN
dpc-517	102	47	=	=	PUNCT
dpc-517	102	48	standard	standard	ADJ
dpc-517	102	49	deviation	deviation	NOUN
dpc-517	102	50	.	.	PUNCT
dpc-517	103	1	table	table	NOUN
dpc-517	103	2	3	3	NUM
dpc-517	103	3	.	.	PUNCT
dpc-517	103	4	improvement	improvement	NOUN
dpc-517	103	5	in	in	ADP
dpc-517	103	6	the	the	DET
dpc-517	103	7	pigmentation	pigmentation	NOUN
dpc-517	103	8	of	of	ADP
dpc-517	103	9	scars	scar	NOUN
dpc-517	103	10	in	in	ADP
dpc-517	103	11	both	both	DET
dpc-517	103	12	groups	group	NOUN
dpc-517	103	13	0	0	NUM
dpc-517	103	14	week	week	NOUN
dpc-517	104	1	24	24	NUM
dpc-517	104	2	weeks	week	NOUN
dpc-517	104	3	pigmentation	pigmentation	VERB
dpc-517	104	4	normal	normal	ADJ
dpc-517	104	5	hypohypernormal	hypohypernormal	ADJ
dpc-517	104	6	hypohyperverapamil	hypohyperverapamil	NOUN
dpc-517	104	7	12	12	NUM
dpc-517	104	8	0	0	NUM
dpc-517	104	9	3	3	NUM
dpc-517	104	10	13	13	NUM
dpc-517	104	11	0	0	NUM
dpc-517	104	12	2	2	NUM
dpc-517	104	13	triamcinolone	triamcinolone	NOUN
dpc-517	104	14	12	12	NUM
dpc-517	104	15	0	0	NUM
dpc-517	104	16	3	3	NUM
dpc-517	104	17	13	13	NUM
dpc-517	104	18	2	2	NUM
dpc-517	104	19	0	0	NUM
dpc-517	104	20	research	research	NOUN
dpc-517	104	21	|	|	ADV
dpc-517	104	22	dermatol	dermatol	NOUN
dpc-517	104	23	pract	pract	NOUN
dpc-517	104	24	concept	concept	NOUN
dpc-517	104	25	2019;9(1):2	2019;9(1):2	VERB
dpc-517	104	26	7	7	NUM
dpc-517	104	27	production	production	NOUN
dpc-517	104	28	.	.	PUNCT
dpc-517	105	1	they	they	PRON
dpc-517	105	2	suggested	suggest	VERB
dpc-517	105	3	that	that	SCONJ
dpc-517	105	4	calcium	calcium	NOUN
dpc-517	105	5	antagonists	antagonist	NOUN
dpc-517	105	6	depolymerize	depolymerize	VERB
dpc-517	105	7	actin	actin	NOUN
dpc-517	105	8	filaments	filament	NOUN
dpc-517	105	9	and	and	CCONJ
dpc-517	105	10	alter	alter	VERB
dpc-517	105	11	the	the	DET
dpc-517	105	12	shape	shape	NOUN
dpc-517	105	13	of	of	ADP
dpc-517	105	14	fibroblast	fibroblast	ADJ
dpc-517	105	15	cells	cell	NOUN
dpc-517	105	16	from	from	ADP
dpc-517	105	17	bipolar	bipolar	ADJ
dpc-517	105	18	to	to	ADP
dpc-517	105	19	spherical	spherical	ADJ
dpc-517	105	20	,	,	PUNCT
dpc-517	105	21	which	which	PRON
dpc-517	105	22	may	may	AUX
dpc-517	105	23	result	result	VERB
dpc-517	105	24	in	in	ADP
dpc-517	105	25	increased	increase	VERB
dpc-517	105	26	procollagenase	procollagenase	NOUN
dpc-517	105	27	production	production	NOUN
dpc-517	106	1	[	[	X
dpc-517	106	2	12	12	NUM
dpc-517	106	3	]	]	PUNCT
dpc-517	106	4	.	.	PUNCT
dpc-517	107	1	shanthi	shanthi	PROPN
dpc-517	107	2	et	et	PROPN
dpc-517	107	3	 	 	SPACE
dpc-517	107	4	al	al	PROPN
dpc-517	107	5	showed	show	VERB
dpc-517	107	6	a	a	DET
dpc-517	107	7	reduction	reduction	NOUN
dpc-517	107	8	in	in	ADP
dpc-517	107	9	vascularity	vascularity	NOUN
dpc-517	107	10	,	,	PUNCT
dpc-517	107	11	pliability	pliability	NOUN
dpc-517	107	12	,	,	PUNCT
dpc-517	107	13	and	and	CCONJ
dpc-517	107	14	height	height	NOUN
dpc-517	107	15	 	 	SPACE
dpc-517	107	16	of	of	ADP
dpc-517	107	17	the	the	DET
dpc-517	107	18	scars	scar	NOUN
dpc-517	107	19	with	with	ADP
dpc-517	107	20	both	both	CCONJ
dpc-517	107	21	triamcinolone	triamcinolone	NOUN
dpc-517	107	22	and	and	CCONJ
dpc-517	107	23	verapamil	verapamil	NOUN
dpc-517	107	24	injections	injection	NOUN
dpc-517	107	25	[	[	X
dpc-517	107	26	5	5	NUM
dpc-517	107	27	]	]	PUNCT
dpc-517	107	28	.	.	PUNCT
dpc-517	108	1	it	it	PRON
dpc-517	108	2	has	have	AUX
dpc-517	108	3	also	also	ADV
dpc-517	108	4	been	be	AUX
dpc-517	108	5	found	find	VERB
dpc-517	108	6	that	that	SCONJ
dpc-517	108	7	this	this	DET
dpc-517	108	8	reduction	reduction	NOUN
dpc-517	108	9	is	be	AUX
dpc-517	108	10	faster	fast	ADJ
dpc-517	108	11	by	by	ADP
dpc-517	108	12	triamcinolone	triamcinolone	NOUN
dpc-517	108	13	injection	injection	NOUN
dpc-517	108	14	.	.	PUNCT
dpc-517	109	1	however	however	ADV
dpc-517	109	2	,	,	PUNCT
dpc-517	109	3	a	a	DET
dpc-517	109	4	desired	desire	VERB
dpc-517	109	5	change	change	NOUN
dpc-517	109	6	in	in	ADP
dpc-517	109	7	pigmentation	pigmentation	NOUN
dpc-517	109	8	was	be	AUX
dpc-517	109	9	not	not	PART
dpc-517	109	10	observed	observe	VERB
dpc-517	109	11	with	with	ADP
dpc-517	109	12	either	either	PRON
dpc-517	109	13	of	of	ADP
dpc-517	109	14	the	the	DET
dpc-517	109	15	drugs	drug	NOUN
dpc-517	109	16	.	.	PUNCT
dpc-517	110	1	they	they	PRON
dpc-517	110	2	found	find	VERB
dpc-517	110	3	that	that	SCONJ
dpc-517	110	4	similar	similar	ADJ
dpc-517	110	5	to	to	ADP
dpc-517	110	6	triamcinolone	triamcinolone	NOUN
dpc-517	110	7	,	,	PUNCT
dpc-517	110	8	verapamil	verapamil	PROPN
dpc-517	110	9	significantly	significantly	ADV
dpc-517	110	10	improved	improve	VERB
dpc-517	110	11	the	the	DET
dpc-517	110	12	clinical	clinical	ADJ
dpc-517	110	13	parameters	parameter	NOUN
dpc-517	110	14	of	of	ADP
dpc-517	110	15	the	the	DET
dpc-517	110	16	scars	scar	NOUN
dpc-517	110	17	;	;	PUNCT
dpc-517	110	18	keloids	keloid	NOUN
dpc-517	110	19	are	be	AUX
dpc-517	110	20	overgrowth	overgrowth	ADJ
dpc-517	110	21	of	of	ADP
dpc-517	110	22	dense	dense	ADJ
dpc-517	110	23	fibrous	fibrous	ADJ
dpc-517	110	24	tissue	tissue	NOUN
dpc-517	110	25	developing	develop	VERB
dpc-517	110	26	after	after	ADP
dpc-517	110	27	trauma	trauma	NOUN
dpc-517	110	28	to	to	ADP
dpc-517	110	29	the	the	DET
dpc-517	110	30	skin	skin	NOUN
dpc-517	110	31	[	[	X
dpc-517	110	32	11	11	NUM
dpc-517	110	33	]	]	PUNCT
dpc-517	110	34	.	.	PUNCT
dpc-517	111	1	although	although	SCONJ
dpc-517	111	2	the	the	DET
dpc-517	111	3	basis	basis	NOUN
dpc-517	111	4	of	of	ADP
dpc-517	111	5	keloid	keloid	ADJ
dpc-517	111	6	formation	formation	NOUN
dpc-517	111	7	has	have	AUX
dpc-517	111	8	not	not	PART
dpc-517	111	9	been	be	AUX
dpc-517	111	10	fully	fully	ADV
dpc-517	111	11	understood	understand	VERB
dpc-517	111	12	,	,	PUNCT
dpc-517	111	13	an	an	DET
dpc-517	111	14	imbalance	imbalance	NOUN
dpc-517	111	15	of	of	ADP
dpc-517	111	16	matrix	matrix	NOUN
dpc-517	111	17	degradation	degradation	NOUN
dpc-517	111	18	and	and	CCONJ
dpc-517	111	19	collagen	collagen	NOUN
dpc-517	111	20	biosynthesis	biosynthesis	NOUN
dpc-517	111	21	,	,	PUNCT
dpc-517	111	22	which	which	PRON
dpc-517	111	23	could	could	AUX
dpc-517	111	24	result	result	VERB
dpc-517	111	25	in	in	ADP
dpc-517	111	26	excess	excess	ADJ
dpc-517	111	27	accumulation	accumulation	NOUN
dpc-517	111	28	of	of	ADP
dpc-517	111	29	collagen	collagen	NOUN
dpc-517	111	30	in	in	ADP
dpc-517	111	31	wound	wound	NOUN
dpc-517	111	32	,	,	PUNCT
dpc-517	111	33	has	have	AUX
dpc-517	111	34	been	be	AUX
dpc-517	111	35	considered	consider	VERB
dpc-517	111	36	the	the	DET
dpc-517	111	37	primary	primary	ADJ
dpc-517	111	38	biochemical	biochemical	ADJ
dpc-517	111	39	feature	feature	NOUN
dpc-517	111	40	of	of	ADP
dpc-517	111	41	these	these	DET
dpc-517	111	42	skin	skin	NOUN
dpc-517	111	43	lesions	lesion	NOUN
dpc-517	111	44	[	[	X
dpc-517	111	45	10	10	NUM
dpc-517	111	46	]	]	PUNCT
dpc-517	111	47	.	.	PUNCT
dpc-517	112	1	furthermore	furthermore	ADV
dpc-517	112	2	,	,	PUNCT
dpc-517	112	3	inflammation	inflammation	NOUN
dpc-517	112	4	or	or	CCONJ
dpc-517	112	5	alteration	alteration	NOUN
dpc-517	112	6	of	of	ADP
dpc-517	112	7	growth	growth	NOUN
dpc-517	112	8	factors	factor	NOUN
dpc-517	112	9	may	may	AUX
dpc-517	112	10	contribute	contribute	VERB
dpc-517	112	11	to	to	PART
dpc-517	112	12	keloid	keloid	VERB
dpc-517	112	13	formation	formation	NOUN
dpc-517	113	1	[	[	X
dpc-517	113	2	11	11	NUM
dpc-517	113	3	]	]	PUNCT
dpc-517	113	4	.	.	PUNCT
dpc-517	114	1	as	as	SCONJ
dpc-517	114	2	cellular	cellular	ADJ
dpc-517	114	3	secretion	secretion	NOUN
dpc-517	114	4	of	of	ADP
dpc-517	114	5	macromolecules	macromolecule	NOUN
dpc-517	114	6	is	be	AUX
dpc-517	114	7	known	know	VERB
dpc-517	114	8	to	to	PART
dpc-517	114	9	be	be	AUX
dpc-517	114	10	a	a	DET
dpc-517	114	11	calcium	calcium	NOUN
dpc-517	114	12	-	-	PUNCT
dpc-517	114	13	dependent	dependent	ADJ
dpc-517	114	14	process	process	NOUN
dpc-517	114	15	,	,	PUNCT
dpc-517	114	16	lee	lee	PROPN
dpc-517	114	17	and	and	CCONJ
dpc-517	114	18	ping	ping	PROPN
dpc-517	114	19	in	in	ADP
dpc-517	114	20	1990	1990	NUM
dpc-517	114	21	examined	examine	VERB
dpc-517	114	22	the	the	DET
dpc-517	114	23	effects	effect	NOUN
dpc-517	114	24	of	of	ADP
dpc-517	114	25	calcium	calcium	NOUN
dpc-517	114	26	antagonists	antagonist	NOUN
dpc-517	114	27	on	on	ADP
dpc-517	114	28	extracellular	extracellular	ADJ
dpc-517	114	29	matrix	matrix	NOUN
dpc-517	114	30	figure	figure	NOUN
dpc-517	114	31	1	1	NUM
dpc-517	114	32	.	.	PUNCT
dpc-517	114	33	line	line	NOUN
dpc-517	114	34	charts	chart	NOUN
dpc-517	114	35	for	for	ADP
dpc-517	114	36	scar	scar	ADJ
dpc-517	114	37	height	height	NOUN
dpc-517	114	38	,	,	PUNCT
dpc-517	114	39	pliability	pliability	NOUN
dpc-517	114	40	,	,	PUNCT
dpc-517	114	41	vascularity	vascularity	NOUN
dpc-517	114	42	and	and	CCONJ
dpc-517	114	43	pigmentation	pigmentation	NOUN
dpc-517	114	44	in	in	ADP
dpc-517	114	45	both	both	DET
dpc-517	114	46	groups	group	NOUN
dpc-517	114	47	.	.	PUNCT
dpc-517	115	1	[	[	X
dpc-517	115	2	copyright	copyright	NOUN
dpc-517	115	3	:	:	PUNCT
dpc-517	115	4	©	©	PROPN
dpc-517	115	5	2019	2019	NUM
dpc-517	115	6	saki	saki	PROPN
dpc-517	115	7	et	et	PROPN
dpc-517	115	8	 	 	SPACE
dpc-517	115	9	al	al	PROPN
dpc-517	115	10	.	.	PROPN
dpc-517	115	11	]	]	PUNCT
dpc-517	116	1	8	8	NUM
dpc-517	116	2	research	research	NOUN
dpc-517	116	3	|	|	ADV
dpc-517	116	4	dermatol	dermatol	NOUN
dpc-517	116	5	pract	pract	PROPN
dpc-517	116	6	concept	concept	NOUN
dpc-517	116	7	2019;9(1):2	2019;9(1):2	PROPN
dpc-517	116	8	compared	compare	VERB
dpc-517	116	9	with	with	ADP
dpc-517	116	10	those	those	PRON
dpc-517	116	11	treated	treat	VERB
dpc-517	116	12	with	with	ADP
dpc-517	116	13	verapamil	verapamil	NOUN
dpc-517	116	14	.	.	PUNCT
dpc-517	117	1	in	in	ADP
dpc-517	117	2	contrast	contrast	NOUN
dpc-517	117	3	to	to	ADP
dpc-517	117	4	studies	study	NOUN
dpc-517	117	5	of	of	ADP
dpc-517	117	6	shanthi	shanthi	PROPN
dpc-517	117	7	et	et	PROPN
dpc-517	117	8	 	 	SPACE
dpc-517	117	9	al	al	PROPN
dpc-517	117	10	[	[	X
dpc-517	117	11	5	5	NUM
dpc-517	117	12	]	]	PUNCT
dpc-517	117	13	and	and	CCONJ
dpc-517	117	14	ahuja	ahuja	PROPN
dpc-517	117	15	and	and	CCONJ
dpc-517	117	16	chatterjee	chatterjee	PROPN
dpc-517	117	17	[	[	X
dpc-517	117	18	6	6	NUM
dpc-517	117	19	]	]	PUNCT
dpc-517	117	20	,	,	PUNCT
dpc-517	117	21	the	the	DET
dpc-517	117	22	scars	scar	NOUN
dpc-517	117	23	of	of	ADP
dpc-517	117	24	both	both	DET
dpc-517	117	25	groups	group	NOUN
dpc-517	117	26	in	in	ADP
dpc-517	117	27	our	our	PRON
dpc-517	117	28	study	study	NOUN
dpc-517	117	29	did	do	AUX
dpc-517	117	30	not	not	PART
dpc-517	117	31	reach	reach	VERB
dpc-517	117	32	complete	complete	ADJ
dpc-517	117	33	flattening	flattening	NOUN
dpc-517	117	34	and	and	CCONJ
dpc-517	117	35	normal	normal	ADJ
dpc-517	117	36	pliability	pliability	NOUN
dpc-517	117	37	at	at	ADP
dpc-517	117	38	the	the	DET
dpc-517	117	39	end	end	NOUN
dpc-517	117	40	of	of	ADP
dpc-517	117	41	the	the	DET
dpc-517	117	42	study	study	NOUN
dpc-517	117	43	.	.	PUNCT
dpc-517	118	1	the	the	DET
dpc-517	118	2	possible	possible	ADJ
dpc-517	118	3	reason	reason	NOUN
dpc-517	118	4	could	could	AUX
dpc-517	118	5	be	be	AUX
dpc-517	118	6	the	the	DET
dpc-517	118	7	higher	high	ADJ
dpc-517	118	8	initial	initial	ADJ
dpc-517	118	9	mean	mean	NOUN
dpc-517	118	10	scores	score	NOUN
dpc-517	118	11	of	of	ADP
dpc-517	118	12	height	height	NOUN
dpc-517	118	13	and	and	CCONJ
dpc-517	118	14	pliability	pliability	NOUN
dpc-517	118	15	in	in	ADP
dpc-517	118	16	both	both	DET
dpc-517	118	17	groups	group	NOUN
dpc-517	118	18	relative	relative	ADJ
dpc-517	118	19	to	to	ADP
dpc-517	118	20	the	the	DET
dpc-517	118	21	mentioned	mention	VERB
dpc-517	118	22	studies	study	NOUN
dpc-517	118	23	.	.	PUNCT
dpc-517	119	1	however	however	ADV
dpc-517	119	2	,	,	PUNCT
dpc-517	119	3	no	no	DET
dpc-517	119	4	significant	significant	ADJ
dpc-517	119	5	difference	difference	NOUN
dpc-517	119	6	was	be	AUX
dpc-517	119	7	found	find	VERB
dpc-517	119	8	in	in	ADP
dpc-517	119	9	the	the	DET
dpc-517	119	10	pigmentation	pigmentation	NOUN
dpc-517	119	11	of	of	ADP
dpc-517	119	12	the	the	DET
dpc-517	119	13	scars	scar	NOUN
dpc-517	119	14	before	before	ADV
dpc-517	119	15	and	and	CCONJ
dpc-517	119	16	after	after	ADP
dpc-517	119	17	treatment	treatment	NOUN
dpc-517	119	18	in	in	ADP
dpc-517	119	19	both	both	DET
dpc-517	119	20	groups	group	NOUN
dpc-517	119	21	.	.	PUNCT
dpc-517	120	1	it	it	PRON
dpc-517	120	2	could	could	AUX
dpc-517	120	3	be	be	AUX
dpc-517	120	4	due	due	ADJ
dpc-517	120	5	to	to	ADP
dpc-517	120	6	the	the	DET
dpc-517	120	7	fact	fact	NOUN
dpc-517	120	8	that	that	SCONJ
dpc-517	120	9	most	most	ADJ
dpc-517	120	10	of	of	ADP
dpc-517	120	11	the	the	DET
dpc-517	120	12	scars	scar	NOUN
dpc-517	120	13	had	have	AUX
dpc-517	120	14	normal	normal	ADJ
dpc-517	120	15	pigmentation	pigmentation	NOUN
dpc-517	120	16	at	at	ADP
dpc-517	120	17	the	the	DET
dpc-517	120	18	beginning	beginning	NOUN
dpc-517	120	19	of	of	ADP
dpc-517	120	20	our	our	PRON
dpc-517	120	21	study	study	NOUN
dpc-517	120	22	.	.	PUNCT
dpc-517	121	1	this	this	DET
dpc-517	121	2	finding	finding	NOUN
dpc-517	121	3	is	be	AUX
dpc-517	121	4	compatible	compatible	ADJ
dpc-517	121	5	with	with	ADP
dpc-517	121	6	previous	previous	ADJ
dpc-517	121	7	studies	study	NOUN
dpc-517	121	8	.	.	PUNCT
dpc-517	122	1	however	however	ADV
dpc-517	122	2	,	,	PUNCT
dpc-517	122	3	in	in	ADP
dpc-517	122	4	contrast	contrast	NOUN
dpc-517	122	5	to	to	ADP
dpc-517	122	6	previous	previous	ADJ
dpc-517	122	7	works	work	NOUN
dpc-517	122	8	,	,	PUNCT
dpc-517	122	9	scar	scar	NOUN
dpc-517	122	10	vascularity	vascularity	NOUN
dpc-517	122	11	did	do	AUX
dpc-517	122	12	not	not	PART
dpc-517	122	13	show	show	VERB
dpc-517	122	14	significant	significant	ADJ
dpc-517	122	15	difference	difference	NOUN
dpc-517	122	16	with	with	ADP
dpc-517	122	17	both	both	DET
dpc-517	122	18	treatments	treatment	NOUN
dpc-517	122	19	at	at	ADP
dpc-517	122	20	the	the	DET
dpc-517	122	21	end	end	NOUN
dpc-517	122	22	of	of	ADP
dpc-517	122	23	our	our	PRON
dpc-517	122	24	study	study	NOUN
dpc-517	122	25	[	[	X
dpc-517	122	26	5,6	5,6	NUM
dpc-517	122	27	]	]	PUNCT
dpc-517	122	28	.	.	PUNCT
dpc-517	123	1	the	the	DET
dpc-517	123	2	results	result	NOUN
dpc-517	123	3	of	of	ADP
dpc-517	123	4	the	the	DET
dpc-517	123	5	present	present	ADJ
dpc-517	123	6	study	study	NOUN
dpc-517	123	7	suggest	suggest	VERB
dpc-517	123	8	that	that	SCONJ
dpc-517	123	9	verapamil	verapamil	NOUN
dpc-517	123	10	can	can	AUX
dpc-517	123	11	be	be	AUX
dpc-517	123	12	considered	consider	VERB
dpc-517	123	13	a	a	DET
dpc-517	123	14	safe	safe	ADJ
dpc-517	123	15	treatment	treatment	NOUN
dpc-517	123	16	for	for	ADP
dpc-517	123	17	patients	patient	NOUN
dpc-517	123	18	with	with	ADP
dpc-517	123	19	keloids	keloid	NOUN
dpc-517	123	20	,	,	PUNCT
dpc-517	123	21	but	but	CCONJ
dpc-517	123	22	it	it	PRON
dpc-517	123	23	is	be	AUX
dpc-517	123	24	not	not	PART
dpc-517	123	25	as	as	ADV
dpc-517	123	26	effective	effective	ADJ
dpc-517	123	27	as	as	ADP
dpc-517	123	28	triamcinolone	triamcinolone	NOUN
dpc-517	123	29	.	.	PUNCT
dpc-517	124	1	to	to	ADP
dpc-517	124	2	date	date	NOUN
dpc-517	124	3	,	,	PUNCT
dpc-517	124	4	corticosteroid	corticosteroid	ADJ
dpc-517	124	5	injection	injection	NOUN
dpc-517	124	6	is	be	AUX
dpc-517	124	7	the	the	DET
dpc-517	124	8	core	core	ADJ
dpc-517	124	9	treatment	treatment	NOUN
dpc-517	124	10	available	available	ADJ
dpc-517	124	11	for	for	ADP
dpc-517	124	12	keloid	keloid	NOUN
dpc-517	124	13	management	management	NOUN
dpc-517	124	14	.	.	PUNCT
dpc-517	125	1	corticosteroids	corticosteroid	NOUN
dpc-517	125	2	suppress	suppress	VERB
dpc-517	125	3	keloid	keloid	ADJ
dpc-517	125	4	formation	formation	NOUN
dpc-517	125	5	by	by	ADP
dpc-517	125	6	3	3	NUM
dpc-517	125	7	different	different	ADJ
dpc-517	125	8	mechanisms	mechanism	NOUN
dpc-517	125	9	.	.	PUNCT
dpc-517	126	1	first	first	ADV
dpc-517	126	2	,	,	PUNCT
dpc-517	126	3	they	they	PRON
dpc-517	126	4	suppress	suppress	VERB
dpc-517	126	5	inflammation	inflammation	NOUN
dpc-517	126	6	by	by	ADP
dpc-517	126	7	inhibition	inhibition	NOUN
dpc-517	126	8	of	of	ADP
dpc-517	126	9	leukocyte	leukocyte	NOUN
dpc-517	126	10	and	and	CCONJ
dpc-517	126	11	monocyte	monocyte	NOUN
dpc-517	126	12	migration	migration	NOUN
dpc-517	126	13	and	and	CCONJ
dpc-517	126	14	phagocytosis	phagocytosis	NOUN
dpc-517	126	15	.	.	PUNCT
dpc-517	127	1	second	second	ADJ
dpc-517	127	2	,	,	PUNCT
dpc-517	127	3	corticosteroids	corticosteroid	NOUN
dpc-517	127	4	are	be	AUX
dpc-517	127	5	potent	potent	ADJ
dpc-517	127	6	vasoconstrictors	vasoconstrictor	NOUN
dpc-517	127	7	that	that	PRON
dpc-517	127	8	reduce	reduce	VERB
dpc-517	127	9	delivery	delivery	NOUN
dpc-517	127	10	of	of	ADP
dpc-517	127	11	oxygen	oxygen	NOUN
dpc-517	127	12	and	and	CCONJ
dpc-517	127	13	nutrients	nutrient	NOUN
dpc-517	127	14	to	to	ADP
dpc-517	127	15	the	the	DET
dpc-517	127	16	wound	wound	NOUN
dpc-517	127	17	.	.	PUNCT
dpc-517	128	1	third	third	ADJ
dpc-517	128	2	,	,	PUNCT
dpc-517	128	3	the	the	DET
dpc-517	128	4	antimitotic	antimitotic	ADJ
dpc-517	128	5	effect	effect	NOUN
dpc-517	128	6	of	of	ADP
dpc-517	128	7	corticosteroids	corticosteroid	NOUN
dpc-517	128	8	inhibits	inhibit	VERB
dpc-517	128	9	proliferation	proliferation	NOUN
dpc-517	128	10	of	of	ADP
dpc-517	128	11	keratinocytes	keratinocyte	NOUN
dpc-517	128	12	and	and	CCONJ
dpc-517	128	13	fibroblasts	fibroblast	NOUN
dpc-517	128	14	,	,	PUNCT
dpc-517	128	15	slowing	slow	VERB
dpc-517	128	16	reepithelialization	reepithelialization	NOUN
dpc-517	128	17	and	and	CCONJ
dpc-517	128	18	new	new	ADJ
dpc-517	128	19	collagen	collagen	NOUN
dpc-517	128	20	formation	formation	NOUN
dpc-517	128	21	.	.	PUNCT
dpc-517	129	1	corticosteroid	corticosteroid	ADJ
dpc-517	129	2	injection	injection	NOUN
dpc-517	129	3	decreases	decrease	VERB
dpc-517	129	4	collagen	collagen	NOUN
dpc-517	129	5	and	and	CCONJ
dpc-517	129	6	glycosaminoglycan	glycosaminoglycan	ADJ
dpc-517	129	7	synthesis	synthesis	NOUN
dpc-517	129	8	by	by	ADP
dpc-517	129	9	several	several	ADJ
dpc-517	129	10	mechanisms	mechanism	NOUN
dpc-517	129	11	including	include	VERB
dpc-517	129	12	decline	decline	NOUN
dpc-517	129	13	of	of	ADP
dpc-517	129	14	inflammatory	inflammatory	ADJ
dpc-517	129	15	process	process	NOUN
dpc-517	129	16	in	in	ADP
dpc-517	129	17	the	the	DET
dpc-517	129	18	wound	wound	NOUN
dpc-517	129	19	,	,	PUNCT
dpc-517	129	20	decreasing	decrease	VERB
dpc-517	129	21	fibroblast	fibroblast	ADJ
dpc-517	129	22	proliferation	proliferation	NOUN
dpc-517	129	23	,	,	PUNCT
dpc-517	129	24	and	and	CCONJ
dpc-517	129	25	hypoxia	hypoxia	NOUN
dpc-517	129	26	enhancement	enhancement	NOUN
dpc-517	129	27	.	.	PUNCT
dpc-517	130	1	they	they	PRON
dpc-517	130	2	also	also	ADV
dpc-517	130	3	lead	lead	VERB
dpc-517	130	4	to	to	ADP
dpc-517	130	5	decreased	decrease	VERB
dpc-517	130	6	levels	level	NOUN
dpc-517	130	7	of	of	ADP
dpc-517	130	8	endogenous	endogenous	ADJ
dpc-517	130	9	vascular	vascular	ADJ
dpc-517	130	10	endothelial	endothelial	NOUN
dpc-517	130	11	growth	growth	NOUN
dpc-517	130	12	factor	factor	NOUN
dpc-517	130	13	(	(	PUNCT
dpc-517	130	14	vegf	vegf	PROPN
dpc-517	130	15	)	)	PUNCT
dpc-517	130	16	,	,	PUNCT
dpc-517	130	17	transforming	transform	VERB
dpc-517	130	18	growth	growth	NOUN
dpc-517	130	19	factor	factor	NOUN
dpc-517	130	20	beta	beta	NOUN
dpc-517	130	21	(	(	PUNCT
dpc-517	130	22	tgf	tgf	PROPN
dpc-517	130	23	-	-	PUNCT
dpc-517	130	24	β	β	NOUN
dpc-517	130	25	)	)	PUNCT
dpc-517	130	26	,	,	PUNCT
dpc-517	130	27	and	and	CCONJ
dpc-517	130	28	interleukin-1	interleukin-1	NUM
dpc-517	130	29	(	(	PUNCT
dpc-517	130	30	il-1	il-1	NUM
dpc-517	130	31	)	)	PUNCT
dpc-517	130	32	,	,	PUNCT
dpc-517	130	33	which	which	PRON
dpc-517	130	34	play	play	VERB
dpc-517	130	35	important	important	ADJ
dpc-517	130	36	roles	role	NOUN
dpc-517	130	37	in	in	ADP
dpc-517	130	38	the	the	DET
dpc-517	130	39	process	process	NOUN
dpc-517	130	40	of	of	ADP
dpc-517	130	41	keloid	keloid	ADJ
dpc-517	130	42	formation	formation	NOUN
dpc-517	131	1	[	[	X
dpc-517	131	2	13	13	NUM
dpc-517	131	3	]	]	PUNCT
dpc-517	131	4	.	.	PUNCT
dpc-517	132	1	however	however	ADV
dpc-517	132	2	,	,	PUNCT
dpc-517	132	3	calcium	calcium	NOUN
dpc-517	132	4	antagonists	antagonist	NOUN
dpc-517	132	5	merely	merely	ADV
dpc-517	132	6	affect	affect	VERB
dpc-517	132	7	this	this	DET
dpc-517	132	8	process	process	NOUN
dpc-517	132	9	by	by	ADP
dpc-517	132	10	reduction	reduction	NOUN
dpc-517	132	11	of	of	ADP
dpc-517	132	12	collagen	collagen	NOUN
dpc-517	132	13	production	production	NOUN
dpc-517	132	14	in	in	ADP
dpc-517	132	15	the	the	DET
dpc-517	132	16	extracellular	extracellular	ADJ
dpc-517	132	17	matrix	matrix	NOUN
dpc-517	132	18	and	and	CCONJ
dpc-517	132	19	stimulation	stimulation	NOUN
dpc-517	132	20	of	of	ADP
dpc-517	132	21	collagenase	collagenase	NOUN
dpc-517	132	22	synthesis	synthesis	NOUN
dpc-517	132	23	,	,	PUNCT
dpc-517	132	24	which	which	PRON
dpc-517	132	25	will	will	AUX
dpc-517	132	26	decrease	decrease	VERB
dpc-517	132	27	fibrous	fibrous	ADJ
dpc-517	132	28	tissue	tissue	NOUN
dpc-517	132	29	production	production	NOUN
dpc-517	132	30	[	[	X
dpc-517	132	31	7	7	NUM
dpc-517	132	32	]	]	PUNCT
dpc-517	132	33	.	.	PUNCT
dpc-517	133	1	conclusions	conclusion	NOUN
dpc-517	133	2	in	in	ADP
dpc-517	133	3	conclusion	conclusion	NOUN
dpc-517	133	4	,	,	PUNCT
dpc-517	133	5	given	give	VERB
dpc-517	133	6	the	the	DET
dpc-517	133	7	anti	anti	ADJ
dpc-517	133	8	-	-	ADJ
dpc-517	133	9	inflammatory	inflammatory	ADJ
dpc-517	133	10	and	and	CCONJ
dpc-517	133	11	antimitotic	antimitotic	ADJ
dpc-517	133	12	effects	effect	NOUN
dpc-517	133	13	of	of	ADP
dpc-517	133	14	triamcinolone	triamcinolone	NOUN
dpc-517	133	15	plus	plus	CCONJ
dpc-517	133	16	its	its	PRON
dpc-517	133	17	vasoconstrictor	vasoconstrictor	NOUN
dpc-517	133	18	properties	property	NOUN
dpc-517	133	19	,	,	PUNCT
dpc-517	133	20	triamcinolone	triamcinolone	PROPN
dpc-517	133	21	would	would	AUX
dpc-517	133	22	be	be	AUX
dpc-517	133	23	an	an	DET
dpc-517	133	24	effective	effective	ADJ
dpc-517	133	25	treatment	treatment	NOUN
dpc-517	133	26	for	for	ADP
dpc-517	133	27	keloids	keloid	NOUN
dpc-517	133	28	in	in	ADP
dpc-517	133	29	comparison	comparison	NOUN
dpc-517	133	30	to	to	ADP
dpc-517	133	31	verapamil	verapamil	NOUN
dpc-517	133	32	.	.	PUNCT
dpc-517	134	1	however	however	ADV
dpc-517	134	2	,	,	PUNCT
dpc-517	134	3	further	further	ADJ
dpc-517	134	4	studies	study	NOUN
dpc-517	134	5	involving	involve	VERB
dpc-517	134	6	a	a	DET
dpc-517	134	7	higher	high	ADJ
dpc-517	134	8	number	number	NOUN
dpc-517	134	9	of	of	ADP
dpc-517	134	10	participants	participant	NOUN
dpc-517	134	11	with	with	ADP
dpc-517	134	12	a	a	DET
dpc-517	134	13	longer	long	ADJ
dpc-517	134	14	period	period	NOUN
dpc-517	134	15	of	of	ADP
dpc-517	134	16	observation	observation	NOUN
dpc-517	134	17	are	be	AUX
dpc-517	134	18	encouraged	encourage	VERB
dpc-517	134	19	to	to	PART
dpc-517	134	20	shed	shed	VERB
dpc-517	134	21	more	more	ADJ
dpc-517	134	22	light	light	NOUN
dpc-517	134	23	on	on	ADP
dpc-517	134	24	this	this	DET
dpc-517	134	25	subject	subject	NOUN
dpc-517	134	26	.	.	PUNCT
dpc-517	135	1	references	reference	NOUN
dpc-517	135	2	1	1	NUM
dpc-517	135	3	.	.	PUNCT
dpc-517	135	4	lee	lee	PROPN
dpc-517	135	5	ss	ss	PROPN
dpc-517	135	6	,	,	PUNCT
dpc-517	135	7	yosipovitch	yosipovitch	VERB
dpc-517	135	8	g	g	PROPN
dpc-517	135	9	,	,	PUNCT
dpc-517	135	10	chan	chan	PROPN
dpc-517	135	11	yh	yh	PROPN
dpc-517	135	12	,	,	PUNCT
dpc-517	135	13	goh	goh	PROPN
dpc-517	135	14	cl	cl	NOUN
dpc-517	135	15	.	.	PUNCT
dpc-517	136	1	pruritus	pruritus	PROPN
dpc-517	136	2	,	,	PUNCT
dpc-517	136	3	pain	pain	NOUN
dpc-517	136	4	,	,	PUNCT
dpc-517	136	5	and	and	CCONJ
dpc-517	136	6	small	small	ADJ
dpc-517	136	7	nerve	nerve	NOUN
dpc-517	136	8	fiber	fiber	NOUN
dpc-517	136	9	function	function	NOUN
dpc-517	136	10	in	in	ADP
dpc-517	136	11	keloids	keloid	NOUN
dpc-517	136	12	:	:	PUNCT
dpc-517	136	13	a	a	DET
dpc-517	136	14	controlled	control	VERB
dpc-517	136	15	study	study	NOUN
dpc-517	136	16	.	.	PUNCT
dpc-517	137	1	j	j	PROPN
dpc-517	137	2	am	be	AUX
dpc-517	137	3	acad	acad	ADJ
dpc-517	137	4	dermatol	dermatol	NOUN
dpc-517	137	5	.	.	PUNCT
dpc-517	138	1	2004;51(6):1002	2004;51(6):1002	NUM
dpc-517	138	2	-	-	SYM
dpc-517	138	3	1006	1006	NUM
dpc-517	138	4	.	.	PUNCT
dpc-517	139	1	hence	hence	ADV
dpc-517	139	2	,	,	PUNCT
dpc-517	139	3	it	it	PRON
dpc-517	139	4	can	can	AUX
dpc-517	139	5	be	be	AUX
dpc-517	139	6	a	a	DET
dpc-517	139	7	suitable	suitable	ADJ
dpc-517	139	8	alternative	alternative	NOUN
dpc-517	139	9	to	to	ADP
dpc-517	139	10	triamcinolone	triamcinolone	NOUN
dpc-517	139	11	for	for	ADP
dpc-517	139	12	treatment	treatment	NOUN
dpc-517	139	13	of	of	ADP
dpc-517	139	14	hypertrophic	hypertrophic	ADJ
dpc-517	139	15	scars	scar	NOUN
dpc-517	139	16	and	and	CCONJ
dpc-517	139	17	keloids	keloid	NOUN
dpc-517	139	18	[	[	X
dpc-517	139	19	5	5	NUM
dpc-517	139	20	]	]	PUNCT
dpc-517	139	21	.	.	PUNCT
dpc-517	139	22	 	 	SPACE
dpc-517	140	1	ahuja	ahuja	PROPN
dpc-517	140	2	and	and	CCONJ
dpc-517	140	3	chatterjee	chatterjee	PROPN
dpc-517	140	4	showed	show	VERB
dpc-517	140	5	that	that	SCONJ
dpc-517	140	6	a	a	DET
dpc-517	140	7	faster	fast	ADJ
dpc-517	140	8	rate	rate	NOUN
dpc-517	140	9	of	of	ADP
dpc-517	140	10	improvement	improvement	NOUN
dpc-517	140	11	in	in	ADP
dpc-517	140	12	scar	scar	ADJ
dpc-517	140	13	height	height	NOUN
dpc-517	140	14	,	,	PUNCT
dpc-517	140	15	vascularity	vascularity	NOUN
dpc-517	140	16	,	,	PUNCT
dpc-517	140	17	and	and	CCONJ
dpc-517	140	18	pliability	pliability	NOUN
dpc-517	140	19	is	be	AUX
dpc-517	140	20	achievable	achievable	ADJ
dpc-517	140	21	with	with	ADP
dpc-517	140	22	triamcinolone	triamcinolone	PROPN
dpc-517	140	23	.	.	PUNCT
dpc-517	141	1	however	however	ADV
dpc-517	141	2	,	,	PUNCT
dpc-517	141	3	the	the	DET
dpc-517	141	4	difference	difference	NOUN
dpc-517	141	5	in	in	ADP
dpc-517	141	6	the	the	DET
dpc-517	141	7	rate	rate	NOUN
dpc-517	141	8	of	of	ADP
dpc-517	141	9	pigmentation	pigmentation	NOUN
dpc-517	141	10	change	change	NOUN
dpc-517	141	11	by	by	ADP
dpc-517	141	12	the	the	DET
dpc-517	141	13	2	2	NUM
dpc-517	141	14	agents	agent	NOUN
dpc-517	141	15	was	be	AUX
dpc-517	141	16	not	not	PART
dpc-517	141	17	statistically	statistically	ADV
dpc-517	141	18	significant	significant	ADJ
dpc-517	141	19	[	[	X
dpc-517	141	20	6	6	NUM
dpc-517	141	21	]	]	PUNCT
dpc-517	141	22	.	.	PUNCT
dpc-517	142	1	the	the	DET
dpc-517	142	2	present	present	ADJ
dpc-517	142	3	study	study	NOUN
dpc-517	142	4	was	be	AUX
dpc-517	142	5	a	a	DET
dpc-517	142	6	randomized	randomized	ADJ
dpc-517	142	7	,	,	PUNCT
dpc-517	142	8	single	single	ADJ
dpc-517	142	9	-	-	PUNCT
dpc-517	142	10	blind	blind	ADJ
dpc-517	142	11	clinical	clinical	ADJ
dpc-517	142	12	trial	trial	NOUN
dpc-517	142	13	comparing	compare	VERB
dpc-517	142	14	the	the	DET
dpc-517	142	15	efficacy	efficacy	NOUN
dpc-517	142	16	of	of	ADP
dpc-517	142	17	intralesional	intralesional	ADJ
dpc-517	142	18	verapamil	verapamil	NOUN
dpc-517	142	19	with	with	ADP
dpc-517	142	20	intralesional	intralesional	ADJ
dpc-517	142	21	triamcinolone	triamcinolone	NOUN
dpc-517	142	22	in	in	ADP
dpc-517	142	23	the	the	DET
dpc-517	142	24	treatment	treatment	NOUN
dpc-517	142	25	of	of	ADP
dpc-517	142	26	keloids	keloid	NOUN
dpc-517	142	27	.	.	PUNCT
dpc-517	143	1	a	a	DET
dpc-517	143	2	significant	significant	ADJ
dpc-517	143	3	improvement	improvement	NOUN
dpc-517	143	4	was	be	AUX
dpc-517	143	5	observed	observe	VERB
dpc-517	143	6	in	in	ADP
dpc-517	143	7	the	the	DET
dpc-517	143	8	height	height	NOUN
dpc-517	143	9	and	and	CCONJ
dpc-517	143	10	pliability	pliability	NOUN
dpc-517	143	11	of	of	ADP
dpc-517	143	12	the	the	DET
dpc-517	143	13	scars	scar	NOUN
dpc-517	143	14	in	in	ADP
dpc-517	143	15	both	both	DET
dpc-517	143	16	groups	group	NOUN
dpc-517	143	17	.	.	PUNCT
dpc-517	144	1	in	in	ADP
dpc-517	144	2	agreement	agreement	NOUN
dpc-517	144	3	with	with	ADP
dpc-517	144	4	the	the	DET
dpc-517	144	5	literature	literature	NOUN
dpc-517	144	6	,	,	PUNCT
dpc-517	144	7	the	the	DET
dpc-517	144	8	improvement	improvement	NOUN
dpc-517	144	9	of	of	ADP
dpc-517	144	10	these	these	DET
dpc-517	144	11	parameters	parameter	NOUN
dpc-517	144	12	was	be	AUX
dpc-517	144	13	significantly	significantly	ADV
dpc-517	144	14	higher	high	ADJ
dpc-517	144	15	in	in	ADP
dpc-517	144	16	the	the	DET
dpc-517	144	17	scars	scar	NOUN
dpc-517	144	18	treated	treat	VERB
dpc-517	144	19	with	with	ADP
dpc-517	144	20	triamcinolone	triamcinolone	NOUN
dpc-517	144	21	figure	figure	NOUN
dpc-517	144	22	2	2	NUM
dpc-517	144	23	.	.	PUNCT
dpc-517	144	24	before	before	ADP
dpc-517	144	25	and	and	CCONJ
dpc-517	144	26	after	after	ADP
dpc-517	144	27	photographs	photograph	NOUN
dpc-517	144	28	of	of	ADP
dpc-517	144	29	a	a	DET
dpc-517	144	30	patient	patient	NOUN
dpc-517	144	31	in	in	ADP
dpc-517	144	32	the	the	DET
dpc-517	144	33	triamcinolone	triamcinolone	NOUN
dpc-517	144	34	group	group	NOUN
dpc-517	144	35	.	.	PUNCT
dpc-517	145	1	[	[	X
dpc-517	145	2	copyright	copyright	NOUN
dpc-517	145	3	:	:	PUNCT
dpc-517	145	4	©	©	PROPN
dpc-517	145	5	2019	2019	NUM
dpc-517	145	6	saki	saki	PROPN
dpc-517	145	7	et	et	PROPN
dpc-517	145	8	 	 	SPACE
dpc-517	145	9	al	al	PROPN
dpc-517	145	10	.	.	PROPN
dpc-517	145	11	]	]	PUNCT
dpc-517	145	12	figure	figure	NOUN
dpc-517	145	13	3	3	NUM
dpc-517	145	14	.	.	PUNCT
dpc-517	145	15	before	before	ADP
dpc-517	145	16	and	and	CCONJ
dpc-517	145	17	after	after	ADP
dpc-517	145	18	photographs	photograph	NOUN
dpc-517	145	19	of	of	ADP
dpc-517	145	20	a	a	DET
dpc-517	145	21	patient	patient	NOUN
dpc-517	145	22	in	in	ADP
dpc-517	145	23	the	the	DET
dpc-517	145	24	verapamil	verapamil	NOUN
dpc-517	145	25	group	group	NOUN
dpc-517	145	26	.	.	PUNCT
dpc-517	146	1	[	[	X
dpc-517	146	2	copyright	copyright	NOUN
dpc-517	146	3	:	:	PUNCT
dpc-517	146	4	©	©	PROPN
dpc-517	146	5	2019	2019	NUM
dpc-517	146	6	saki	saki	PROPN
dpc-517	146	7	et	et	PROPN
dpc-517	146	8	 	 	SPACE
dpc-517	146	9	al	al	PROPN
dpc-517	146	10	.	.	PROPN
dpc-517	146	11	]	]	PUNCT
dpc-517	147	1	research	research	NOUN
dpc-517	147	2	|	|	ADV
dpc-517	147	3	dermatol	dermatol	NOUN
dpc-517	147	4	pract	pract	NOUN
dpc-517	147	5	concept	concept	NOUN
dpc-517	147	6	2019;9(1):2	2019;9(1):2	VERB
dpc-517	147	7	9	9	NUM
dpc-517	147	8	8	8	NUM
dpc-517	147	9	.	.	PUNCT
dpc-517	148	1	sullivan	sullivan	PROPN
dpc-517	148	2	ta	ta	PROPN
dpc-517	148	3	,	,	PUNCT
dpc-517	148	4	smith	smith	PROPN
dpc-517	148	5	j	j	PROPN
dpc-517	148	6	,	,	PUNCT
dpc-517	148	7	kermode	kermode	PROPN
dpc-517	148	8	j	j	PROPN
dpc-517	148	9	,	,	PUNCT
dpc-517	148	10	mclver	mclver	NOUN
dpc-517	148	11	e	e	PROPN
dpc-517	148	12	,	,	PUNCT
dpc-517	148	13	courtemanche	courtemanche	PROPN
dpc-517	148	14	d.	d.	PROPN
dpc-517	148	15	rating	rate	VERB
dpc-517	148	16	the	the	DET
dpc-517	148	17	burn	burn	NOUN
dpc-517	148	18	scar	scar	NOUN
dpc-517	148	19	.	.	PUNCT
dpc-517	149	1	j	j	PROPN
dpc-517	149	2	burn	burn	VERB
dpc-517	149	3	care	care	NOUN
dpc-517	149	4	rehabil	rehabil	NOUN
dpc-517	149	5	.	.	PUNCT
dpc-517	150	1	1990;11(3):256	1990;11(3):256	NUM
dpc-517	150	2	-	-	SYM
dpc-517	150	3	260	260	NUM
dpc-517	150	4	.	.	NOUN
dpc-517	151	1	9	9	NUM
dpc-517	151	2	.	.	X
dpc-517	151	3	mofikoya	mofikoya	PROPN
dpc-517	151	4	bo	bo	PROPN
dpc-517	151	5	,	,	PUNCT
dpc-517	151	6	adeyemo	adeyemo	PROPN
dpc-517	151	7	wl	wl	PROPN
dpc-517	151	8	,	,	PUNCT
dpc-517	151	9	abdus	abdus	PROPN
dpc-517	151	10	-	-	PUNCT
dpc-517	151	11	salam	salam	PROPN
dpc-517	151	12	aa	aa	PROPN
dpc-517	151	13	.	.	PUNCT
dpc-517	152	1	keloid	keloid	PROPN
dpc-517	152	2	and	and	CCONJ
dpc-517	152	3	hypertrophic	hypertrophic	ADJ
dpc-517	152	4	scars	scar	NOUN
dpc-517	152	5	:	:	PUNCT
dpc-517	152	6	a	a	DET
dpc-517	152	7	review	review	NOUN
dpc-517	152	8	of	of	ADP
dpc-517	152	9	recent	recent	ADJ
dpc-517	152	10	developments	development	NOUN
dpc-517	152	11	in	in	ADP
dpc-517	152	12	pathogenesis	pathogenesis	NOUN
dpc-517	152	13	and	and	CCONJ
dpc-517	152	14	management	management	NOUN
dpc-517	152	15	.	.	PUNCT
dpc-517	153	1	nig	nig	PROPN
dpc-517	153	2	q	q	PROPN
dpc-517	153	3	j	j	PROPN
dpc-517	153	4	hosp	hosp	PROPN
dpc-517	153	5	med	med	PROPN
dpc-517	153	6	.	.	PUNCT
dpc-517	154	1	2007;17(4):134	2007;17(4):134	NUM
dpc-517	154	2	-	-	SYM
dpc-517	154	3	139	139	NUM
dpc-517	154	4	.	.	PUNCT
dpc-517	155	1	10	10	NUM
dpc-517	155	2	.	.	PUNCT
dpc-517	156	1	manuskiatti	manuskiatti	PROPN
dpc-517	156	2	w	w	PROPN
dpc-517	156	3	,	,	PUNCT
dpc-517	156	4	fitzpatrick	fitzpatrick	PROPN
dpc-517	156	5	re	re	PROPN
dpc-517	156	6	.	.	PUNCT
dpc-517	157	1	treatment	treatment	NOUN
dpc-517	157	2	response	response	NOUN
dpc-517	157	3	of	of	ADP
dpc-517	157	4	keloidal	keloidal	ADJ
dpc-517	157	5	and	and	CCONJ
dpc-517	157	6	hypertrophic	hypertrophic	ADJ
dpc-517	157	7	sternotomy	sternotomy	NOUN
dpc-517	157	8	scars	scar	NOUN
dpc-517	157	9	:	:	PUNCT
dpc-517	157	10	comparison	comparison	NOUN
dpc-517	157	11	among	among	ADP
dpc-517	157	12	intralesional	intralesional	ADJ
dpc-517	157	13	corticosteroid	corticosteroid	ADJ
dpc-517	157	14	,	,	PUNCT
dpc-517	157	15	5	5	NUM
dpc-517	157	16	-	-	PUNCT
dpc-517	157	17	fluorouracil	fluorouracil	NOUN
dpc-517	157	18	,	,	PUNCT
dpc-517	157	19	and	and	CCONJ
dpc-517	157	20	585	585	NUM
dpc-517	157	21	-	-	PUNCT
dpc-517	157	22	nm	nm	ADJ
dpc-517	157	23	flashlamp	flashlamp	NOUN
dpc-517	157	24	-	-	PUNCT
dpc-517	157	25	pumped	pump	VERB
dpc-517	157	26	pulsed	pulse	VERB
dpc-517	157	27	-	-	PUNCT
dpc-517	157	28	dye	dye	NOUN
dpc-517	157	29	laser	laser	NOUN
dpc-517	157	30	treatments	treatment	NOUN
dpc-517	157	31	.	.	PUNCT
dpc-517	158	1	arch	arch	ADJ
dpc-517	158	2	dermatol	dermatol	NOUN
dpc-517	158	3	.	.	PUNCT
dpc-517	159	1	2002;138(9):1149	2002;138(9):1149	NUM
dpc-517	159	2	-	-	SYM
dpc-517	159	3	1155	1155	NUM
dpc-517	159	4	.	.	PUNCT
dpc-517	160	1	11	11	NUM
dpc-517	160	2	.	.	PUNCT
dpc-517	161	1	leventhal	leventhal	PROPN
dpc-517	161	2	d	d	PROPN
dpc-517	161	3	,	,	PUNCT
dpc-517	161	4	furr	furr	PROPN
dpc-517	161	5	m	m	PROPN
dpc-517	161	6	,	,	PUNCT
dpc-517	161	7	reiter	reiter	PROPN
dpc-517	161	8	d.	d.	PROPN
dpc-517	161	9	treatment	treatment	PROPN
dpc-517	161	10	of	of	ADP
dpc-517	161	11	keloids	keloid	NOUN
dpc-517	161	12	and	and	CCONJ
dpc-517	161	13	hypertrophic	hypertrophic	ADJ
dpc-517	161	14	scars	scar	NOUN
dpc-517	161	15	:	:	PUNCT
dpc-517	161	16	a	a	DET
dpc-517	161	17	meta	meta	ADJ
dpc-517	161	18	-	-	PUNCT
dpc-517	161	19	analysis	analysis	NOUN
dpc-517	161	20	and	and	CCONJ
dpc-517	161	21	review	review	NOUN
dpc-517	161	22	of	of	ADP
dpc-517	161	23	the	the	DET
dpc-517	161	24	literature	literature	NOUN
dpc-517	161	25	.	.	PUNCT
dpc-517	162	1	arch	arch	ADJ
dpc-517	162	2	facial	facial	ADJ
dpc-517	162	3	plast	plast	NOUN
dpc-517	162	4	surg	surg	NOUN
dpc-517	162	5	.	.	PUNCT
dpc-517	163	1	2006;8(6):362	2006;8(6):362	NUM
dpc-517	163	2	-	-	PUNCT
dpc-517	163	3	368	368	NUM
dpc-517	163	4	.	.	PUNCT
dpc-517	164	1	12	12	NUM
dpc-517	164	2	.	.	PUNCT
dpc-517	165	1	lee	lee	PROPN
dpc-517	165	2	rc	rc	PROPN
dpc-517	165	3	,	,	PUNCT
dpc-517	165	4	ping	ping	PROPN
dpc-517	165	5	ja	ja	PROPN
dpc-517	165	6	.	.	PUNCT
dpc-517	165	7	calcium	calcium	NOUN
dpc-517	165	8	antagonists	antagonist	NOUN
dpc-517	165	9	retard	retard	VERB
dpc-517	165	10	extracellular	extracellular	ADJ
dpc-517	165	11	matrix	matrix	NOUN
dpc-517	165	12	production	production	NOUN
dpc-517	165	13	in	in	ADP
dpc-517	165	14	connective	connective	ADJ
dpc-517	165	15	tissue	tissue	NOUN
dpc-517	165	16	equivalent	equivalent	ADJ
dpc-517	165	17	.	.	PUNCT
dpc-517	166	1	j	j	PROPN
dpc-517	166	2	surg	surg	PROPN
dpc-517	166	3	res	re	NOUN
dpc-517	166	4	.	.	PUNCT
dpc-517	167	1	1990;49(5):463	1990;49(5):463	NUM
dpc-517	167	2	-	-	NUM
dpc-517	167	3	466	466	NUM
dpc-517	167	4	.	.	NOUN
dpc-517	167	5	13	13	NUM
dpc-517	167	6	.	.	PUNCT
dpc-517	168	1	roques	roque	NOUN
dpc-517	168	2	c	c	PROPN
dpc-517	168	3	,	,	PUNCT
dpc-517	168	4	téot	téot	PROPN
dpc-517	168	5	l.	l.	PROPN
dpc-517	169	1	the	the	DET
dpc-517	169	2	use	use	NOUN
dpc-517	169	3	of	of	ADP
dpc-517	169	4	corticosteroids	corticosteroid	NOUN
dpc-517	169	5	to	to	PART
dpc-517	169	6	treat	treat	VERB
dpc-517	169	7	keloids	keloid	NOUN
dpc-517	169	8	:	:	PUNCT
dpc-517	169	9	a	a	DET
dpc-517	169	10	review	review	NOUN
dpc-517	169	11	.	.	PUNCT
dpc-517	170	1	int	int	PROPN
dpc-517	170	2	j	j	PROPN
dpc-517	170	3	low	low	PROPN
dpc-517	170	4	extrem	extrem	PROPN
dpc-517	170	5	wounds	wound	NOUN
dpc-517	170	6	.	.	PUNCT
dpc-517	171	1	2008;7(3):137	2008;7(3):137	NUM
dpc-517	171	2	-	-	SYM
dpc-517	171	3	145	145	NUM
dpc-517	171	4	.	.	PUNCT
dpc-517	172	1	2	2	X
dpc-517	172	2	.	.	X
dpc-517	172	3	garg	garg	PROPN
dpc-517	172	4	am	am	PROPN
dpc-517	172	5	,	,	PUNCT
dpc-517	172	6	shah	shah	PROPN
dpc-517	172	7	ym	ym	PROPN
dpc-517	172	8	,	,	PUNCT
dpc-517	172	9	garg	garg	PROPN
dpc-517	172	10	a	a	PRON
dpc-517	172	11	,	,	PUNCT
dpc-517	172	12	et	et	PROPN
dpc-517	172	13	 	 	SPACE
dpc-517	172	14	al	al	PROPN
dpc-517	172	15	.	.	PUNCT
dpc-517	173	1	the	the	DET
dpc-517	173	2	efficacy	efficacy	NOUN
dpc-517	173	3	of	of	ADP
dpc-517	173	4	intralesional	intralesional	ADJ
dpc-517	173	5	triamcinolone	triamcinolone	NOUN
dpc-517	173	6	acetonide	acetonide	NOUN
dpc-517	173	7	(	(	PUNCT
dpc-517	173	8	20mg	20mg	NOUN
dpc-517	173	9	/	/	SYM
dpc-517	173	10	ml	ml	VERB
dpc-517	173	11	)	)	PUNCT
dpc-517	173	12	in	in	ADP
dpc-517	173	13	the	the	DET
dpc-517	173	14	treatment	treatment	NOUN
dpc-517	173	15	of	of	ADP
dpc-517	173	16	keloid	keloid	NOUN
dpc-517	173	17	.	.	PUNCT
dpc-517	174	1	int	int	NOUN
dpc-517	174	2	surg	surg	PROPN
dpc-517	174	3	j.	j.	PROPN
dpc-517	174	4	2018;5(3):868	2018;5(3):868	PROPN
dpc-517	174	5	-	-	SYM
dpc-517	174	6	872	872	NUM
dpc-517	174	7	.	.	PUNCT
dpc-517	175	1	3	3	X
dpc-517	175	2	.	.	X
dpc-517	175	3	robles	robles	PROPN
dpc-517	175	4	dt	dt	PROPN
dpc-517	175	5	,	,	PUNCT
dpc-517	175	6	berg	berg	PROPN
dpc-517	175	7	d.	d.	PROPN
dpc-517	175	8	abnormal	abnormal	ADJ
dpc-517	175	9	wound	wound	NOUN
dpc-517	175	10	healing	healing	NOUN
dpc-517	175	11	:	:	PUNCT
dpc-517	175	12	keloids	keloid	NOUN
dpc-517	175	13	.	.	PUNCT
dpc-517	176	1	clin	clin	PROPN
dpc-517	176	2	dermatol	dermatol	NOUN
dpc-517	176	3	.	.	PUNCT
dpc-517	177	1	2007;25(1):26	2007;25(1):26	NUM
dpc-517	177	2	-	-	SYM
dpc-517	177	3	32	32	NUM
dpc-517	177	4	.	.	PUNCT
dpc-517	178	1	4	4	X
dpc-517	178	2	.	.	X
dpc-517	178	3	gauglitz	gauglitz	PROPN
dpc-517	178	4	gg	gg	PROPN
dpc-517	178	5	,	,	PUNCT
dpc-517	178	6	korting	korte	VERB
dpc-517	178	7	hc	hc	PRON
dpc-517	178	8	,	,	PUNCT
dpc-517	178	9	pavicic	pavicic	PROPN
dpc-517	178	10	t	t	PROPN
dpc-517	178	11	,	,	PUNCT
dpc-517	178	12	ruzicka	ruzicka	PROPN
dpc-517	178	13	t	t	PROPN
dpc-517	178	14	,	,	PUNCT
dpc-517	178	15	jeschke	jeschke	NOUN
dpc-517	178	16	mg	mg	PROPN
dpc-517	178	17	.	.	PUNCT
dpc-517	178	18	hypertrophic	hypertrophic	ADJ
dpc-517	178	19	scarring	scarring	NOUN
dpc-517	178	20	and	and	CCONJ
dpc-517	178	21	keloids	keloid	NOUN
dpc-517	178	22	:	:	PUNCT
dpc-517	178	23	pathomechanisms	pathomechanism	NOUN
dpc-517	178	24	and	and	CCONJ
dpc-517	178	25	current	current	ADJ
dpc-517	178	26	and	and	CCONJ
dpc-517	178	27	emerging	emerge	VERB
dpc-517	178	28	treatment	treatment	NOUN
dpc-517	178	29	strategies	strategy	NOUN
dpc-517	178	30	.	.	PUNCT
dpc-517	179	1	mol	mol	ADP
dpc-517	179	2	med	med	ADJ
dpc-517	179	3	.	.	PUNCT
dpc-517	180	1	2011;17(1	2011;17(1	NUM
dpc-517	180	2	-	-	SYM
dpc-517	180	3	2):113	2):113	NUM
dpc-517	180	4	.	.	NOUN
dpc-517	181	1	5	5	NUM
dpc-517	181	2	.	.	PUNCT
dpc-517	181	3	shanthi	shanthi	PROPN
dpc-517	181	4	fm	fm	PROPN
dpc-517	181	5	,	,	PUNCT
dpc-517	181	6	ernest	ernest	PROPN
dpc-517	181	7	k	k	PROPN
dpc-517	181	8	,	,	PUNCT
dpc-517	181	9	dhanraj	dhanraj	ADJ
dpc-517	181	10	p.	p.	NOUN
dpc-517	181	11	comparison	comparison	NOUN
dpc-517	181	12	of	of	ADP
dpc-517	181	13	intralesional	intralesional	ADJ
dpc-517	181	14	verapamil	verapamil	NOUN
dpc-517	181	15	with	with	ADP
dpc-517	181	16	intralesional	intralesional	ADJ
dpc-517	181	17	triamcinolone	triamcinolone	NOUN
dpc-517	181	18	in	in	ADP
dpc-517	181	19	the	the	DET
dpc-517	181	20	treatment	treatment	NOUN
dpc-517	181	21	of	of	ADP
dpc-517	181	22	hypertrophic	hypertrophic	ADJ
dpc-517	181	23	scars	scar	NOUN
dpc-517	181	24	and	and	CCONJ
dpc-517	181	25	keloids	keloid	NOUN
dpc-517	181	26	.	.	PUNCT
dpc-517	182	1	indian	indian	PROPN
dpc-517	182	2	j	j	PROPN
dpc-517	182	3	dermatol	dermatol	PROPN
dpc-517	182	4	venereol	venereol	ADJ
dpc-517	182	5	leprol	leprol	NOUN
dpc-517	182	6	.	.	PUNCT
dpc-517	183	1	2008;74(4):343	2008;74(4):343	NUM
dpc-517	183	2	.	.	PUNCT
dpc-517	184	1	6	6	NUM
dpc-517	184	2	.	.	PUNCT
dpc-517	184	3	ahuja	ahuja	PROPN
dpc-517	184	4	rb	rb	PROPN
dpc-517	184	5	,	,	PUNCT
dpc-517	184	6	chatterjee	chatterjee	PROPN
dpc-517	184	7	p.	p.	PROPN
dpc-517	184	8	comparative	comparative	ADJ
dpc-517	184	9	efficacy	efficacy	NOUN
dpc-517	184	10	of	of	ADP
dpc-517	184	11	intralesional	intralesional	ADJ
dpc-517	184	12	verapamil	verapamil	NOUN
dpc-517	184	13	hydrochloride	hydrochloride	NOUN
dpc-517	184	14	and	and	CCONJ
dpc-517	184	15	triamcinolone	triamcinolone	NOUN
dpc-517	184	16	acetonide	acetonide	NOUN
dpc-517	184	17	in	in	ADP
dpc-517	184	18	hypertrophic	hypertrophic	ADJ
dpc-517	184	19	scars	scar	NOUN
dpc-517	184	20	and	and	CCONJ
dpc-517	184	21	keloids	keloid	NOUN
dpc-517	184	22	.	.	PUNCT
dpc-517	185	1	burns	burn	NOUN
dpc-517	185	2	.	.	PUNCT
dpc-517	186	1	2014;40(4):583	2014;40(4):583	NUM
dpc-517	186	2	-	-	SYM
dpc-517	186	3	588	588	NUM
dpc-517	186	4	.	.	NOUN
dpc-517	187	1	7	7	X
dpc-517	187	2	.	.	NUM
dpc-517	187	3	d’andrea	d’andrea	PROPN
dpc-517	187	4	f	f	X
dpc-517	187	5	,	,	PUNCT
dpc-517	187	6	brongo	brongo	PROPN
dpc-517	187	7	s	s	PART
dpc-517	187	8	,	,	PUNCT
dpc-517	187	9	ferraro	ferraro	PROPN
dpc-517	187	10	g	g	PROPN
dpc-517	187	11	,	,	PUNCT
dpc-517	187	12	baroni	baroni	PROPN
dpc-517	187	13	a.	a.	PROPN
dpc-517	187	14	prevention	prevention	PROPN
dpc-517	187	15	and	and	CCONJ
dpc-517	187	16	treatment	treatment	NOUN
dpc-517	187	17	of	of	ADP
dpc-517	187	18	keloids	keloid	NOUN
dpc-517	187	19	with	with	ADP
dpc-517	187	20	intralesional	intralesional	ADJ
dpc-517	187	21	verapamil	verapamil	NOUN
dpc-517	187	22	.	.	PUNCT
dpc-517	188	1	dermatology	dermatology	NOUN
dpc-517	188	2	.	.	PUNCT
dpc-517	189	1	2002;204(1):60	2002;204(1):60	X
dpc-517	189	2	-	-	PUNCT
dpc-517	189	3	62	62	NUM
dpc-517	189	4	.	.	PUNCT